ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer
Nout, R., Calaminus, G., Planchamp, F., Chargari, C., Lax, S. F., Martelli, H., McCluggage, W. G., Morice, P., Pakiz, M., Schmid, M. P., Stunt, J., Timmermann, B., Vokuhl, C., Orbach, D., & Fotopoulou, C. (2023). ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 186, 109662. https://doi.org/10.1016/j.radonc.2023.109662
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Kurtz, J. E., Pujade-Lauraine, E., Oaknin, A., Belin, L., Leitner, K., Cibula, D., Denys, H., Rosengarten, O., Rodrigues, M., de Gregorio, N., Martinez García, J., Petru, E., Kocián, R., Vergote, I., Pautier, P., Schmalfeldt, B., Gaba, L., Polterauer, S., Mouret Reynier, M. A., Sehouli, J., … ATALANTE/ENGOT-ov29 Investigators (2023). Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2300529. Advance online publication. https://doi.org/10.1200/JCO.23.00529
Stephan Polterauer ORCID (Connecting research and researchers)
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium
Heinzl, N., Maritschnegg, E., Koziel, K., Schilhart-Wallisch, C., Heinze, G., Yang, W. L., Bast, R. C., Sehouli, J., Braicu, E. I., Vergote, I., Van Gorp, T., Mahner, S., Paspalj, V., Grimm, C., Obermayr, E., Schuster, E., Holzer, B., Rousseau, F., Schymkowitz, J., Concin, N., … Zeillinger, R. (2023). Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium. Oncogene, 42(33), 2473–2484. https://doi.org/10.1038/s41388-023-02758-8
Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer
Bartl, T., Alberts, A., Papadopoulos, S. C., Wolf, A., Muellauer, L., Hofstetter, G., Grimm, C., & Cacsire Castillo-Tong, D. (2023). Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 33(9), 1419–1426. https://doi.org/10.1136/ijgc-2023-004360
ORCID: 0000-0002-1938-1574
thomas.bartl@meduniwien.ac.at
Research group(s): Translational Gynecology
Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study
Schmid, M. P., Lindegaard, J. C., Mahantshetty, U., Tanderup, K., Jürgenliemk-Schulz, I., Haie-Meder, C., Fokdal, L. U., Sturdza, A., Hoskin, P., Segedin, B., Bruheim, K., Huang, F., Rai, B., Cooper, R., van der Steen-Banasik, E., Van Limbergen, E., Pieters, B. R., Petric, P., Ramazanova, D., Ristl, R., … EMBRACE Collaborative Group (2023). Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(10), 1933–1942. https://doi.org/10.1200/JCO.22.01096
Image-guided brachytherapy in cervical cancer including fractionation
Sturdza, A. E., & Knoth, J. (2022). Image-guided brachytherapy in cervical cancer including fractionation. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 32(3), 273–280. https://doi.org/10.1136/ijgc-2021-003056
Universitätsklinik für Radioonkologie
Gynäkologische Tumore
E-Mail: alina.sturdza@meduniwien.ac.at
SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer
Koller, S., Kendler, J., Karacs, J., Wolf, A., Kreuzinger, C., Von Der Decken, I., Mungenast, F., Mechtcheriakova, D., Schreiner, W., Gleiss, A., Jäger, W., Cacsire Castillo-Tong, D., & Thalhammer, T. (2022). SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer. Frontiers in pharmacology, 13, 946348. https://doi.org/10.3389/fphar.2022.946348
Manifestation pattern of early-late vaginal morbidity after definitive radio(chemo)therapy and image guided adaptive brachytherapy for locally advanced cervical cancer – An analysis from the EMBRACE study.
Kirchheiner K, Nout RA, Tanderup K, Lindegaard JC, Westerveld H, Haie-Meder C, Petrič P, Mahantshetty U, Dörr W, Pötter R.
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):88-95.
Posttraumatic stress disorder after HDR brachytherapy for cervical cancer with two fractions in one application under spinal/epidural anesthesia: Incidence and risk factors.
Kirchheiner K, Czajka-Pepl A, Ponocny-Seliger E, Scharbert G, Wetzel L, Nout RA, Sturdza A, Dimopoulos JC, Dörr W, Pötter R.
Int J Radiat Oncol Biol Phys. 2014 Apr 7.
Feasibility of transrectal ultrasonography for assessment of cervical cancer.
Schmid MP, Pötter R, Brader P, Kratochwil A, Goldner G, Kirchheiner K, Sturdza AE, Kirisits C.
Strahlenther Onkol. 2013 Feb;189(2):123-8.
Magnetic resonance imaging for assessment of parametrial tumour spread and regression patterns in adaptive cervix cancer radiotherapy.
Schmid MP, Fidarova E, Pötter R, Petric P, Bauer V, Woehs V, Georg P, Kirchheiner K, Berger D, Kirisits C, Dörr W, Dimopoulos JC.
Acta Oncol. 2013 Oct;52(7):1384-90.
Distant metastasis in patients with cervical cancer after primary radiotherapy with or without chemotherapy and image guided adaptive brachytherapy.
Schmid MP and Franckena M, Kirchheiner K et al.
Gynecol Oncol. 2014 May;133(2):256-62.
Bartl, T., Karacs, J., Kreuzinger, C., Pfaffinger, S., Kendler, J., Ciocsirescu, C., Wolf, A., Reinthaller, A., Meyer, E., Brandstetter, M., Postl, M., Langthaler, E., Braicu, E., Vergote, I., Cunnea, P., Gourley, C., Schmitt, W. D., Cacsire Castillo-Tong, D., & Christoph, G. (2021). Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. Cancers, 13(5), 1076.https://doi.org/10.3390/cancers13051076
Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer: Results of the International Multicenter RetroEMBRAVE Cohort Study. Westerveld H, Schmid MP, Nout RA, Chargari C, Pieters BR, Creutzberg CL, Sturdza A, Lindegaard JC, van Kesteren Z, Mazeron R, Nesvacil N, Fokdal LU.Cancers (Basel). 2021 Mar 23;13(6):1459. doi: 10.3390/cancers13061459.
PMID: 33806733 Free PMC article.
Nomogram predicting overall survival in locally advanced cervical cancer patients treated by radio-chemotherapy including image guided brachytherapy: a Retro-EMBRACE study. Sturdza AE, Poetter R, Kossmeier M, Kirchheiner K, Mahantshetty U, Haie-Meder C, Lindegaard JC, Jurgenliemk-Schulz I, Tan LT, Hoskin P, van Limbergen E, Gillham C, Segedin B, Tharavichitkul E, Iturre EV, Fokdal LU, Polterauer S, Kirisits C, Tanderup K.Int J Radiat Oncol Biol Phys. 2021 Apr 28:S0360-3016(21)00404-1. doi: 10.1016/j.ijrobp.2021.04.022. Online ahead of print.PMID: 33932530
Early morbidity and dose-volume effects in definitive radiochemotherapy for locally advanced cervical cancer: a prospective cohort study covering modern treatment techniques. Seppenwoolde Y, Majercakova K, Buschmann M, Dörr E, Sturdza AE, Schmid MP, Pötter R, Georg D.Strahlenther Onkol. 2021 Jun;197(6):505-519. doi: 10.1007/s00066-021-01781-6. Epub 2021 Apr 30.PMID: 33929558 Free PMC article.
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Pötter R, Tanderup K, Schmid MP, Jürgenliemk-Schulz I, Haie-Meder C, Fokdal LU, Sturdza AE, Hoskin P, Mahantshetty U, Segedin B, Bruheim K, Huang F, Rai B, Cooper R, van der Steen-Banasik E, Van Limbergen E, Pieters BR, Tan LT, Nout RA, De Leeuw AAC, Ristl R, Petric P, Nesvacil N, Kirchheiner K, Kirisits C, Lindegaard JC; EMBRACE Collaborative Group.Lancet Oncol. 2021 Apr;224):538-547. doi: 10.1016/S1470-2045(20)30753-1.
PMID: 33794207 Clinical Trial.
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Martin AG, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL.
Radiother Oncol. 2021 Jan;154:327-353. doi: 10.1016/j.radonc.2020.11.018.PMID: 33712263
Response to Yuce Sari et al. Spampinato S, Fokdal LU, Pötter R, Haie-Meder C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van der Steen-Banasik E, Van Limbergen E, Sundset M, Westerveld H, Nout RA, Jensen NBK, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group.
Radiother Oncol. 2021 May;158:323-324. doi: 10.1016/j.radonc.2021.02.022. Epub 2021 Feb 26.
PMID: 33647355 No abstract available.
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, González-Martín A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X.Virchows Arch. 2021 Feb;478(2):153-190. doi: 10.1007/s00428-020-03007-z.
PMID: 33604759
Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. Spampinato S, Fokdal LU, Pötter R, Haie-Meder C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van der Steen-Banasik E, Van Limbergen E, Sundset M, Westerveld H, Nout RA, Jensen NBK, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group.
Radiother Oncol. 2021 May;158:312-320. doi: 10.1016/j.radonc.2021.01.019. Epub 2021 Feb 3.PMID: 33545254
Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study.
Petric P, Lindegaard JC, Sturdza A, Fokdal L, Kirchheiner K, Tan LT, Schmid MP, Haie-Meder C, Jürgenliemk-Schulz IM, van Limbergen E, Hoskin P, Gillham C, Tharavichitkul E, Mahantshetty U, Villafranca E, Tanderup K, Kirisits C, Pötter R.Radiother Oncol. 2021 Apr;157:24-31. doi: 10.1016/j.radonc.2021.01.005. Epub 2021 Jan 19.PMID: 33476724
Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data. Oberndorfer F, Moling S, Hagelkruys LA, Grimm C, Polterauer S, Sturdza A, Aust S, Reinthaller A, Müllauer L, Schwameis R.J Pers Med. 2021 Jan 15;11(1):48. doi: 10.3390/jpm11010048.PMID: 3467460 Free PMC article.
Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands. Schmid MP, Held T, Lang K, Herfarth K, Hörner-Rieber J, Harrabi SB, Moratin J, Freudlsperger C, Zaoui K, Debus J, Adeberg S.Cancers (Basel). 2021 Jan 2;13(1): 90/cancers13010124.
PMID: 33401730 Free PMC article.
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL.Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.PMID: 33397713
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Chopra S, Mangaj A, Sharma A, Tan LT, Sturdza A, Jürgenliemk-Schulz I, Han K, Huang F, Schmid MP, Fokdal L, Chargari C, Diendorfer T, Tanderup K, Potter R, Nout RA.Radiother Oncol. 2021 Feb;155:151-159. doi: 10.1016/j.radonc.2020.10.037. Epub 2020 Nov 2.PMID: 33144247
Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. K Jensen NB, Pötter R, Spampinato S, Fokdal LU, Chargari C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Wiebe E, Cooper R, Van der Steen-Banasik E, Van Limbergen E, Sundset M, Pieters BR, Nout RA, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group.Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):688-700. doi: 10.1016/j.ijrobp.2020.10.006. Epub 2020 Oct 14.PMID: 33068689
»Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. Spampinato S, Fokdal LU, Pötter R, Haie-Meder C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van der Steen-Banasik E, Van Limbergen E, Sundset M, Westerveld H, Nout RA, Jensen NBK, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group.
Radiother Oncol. 2021 May;158:300-308. doi: 10.1016/j.radonc.2020.10.003. Epub 2020 Oct 14.
PMID: 33065183
Initiatives for education, training, and dissemination of morbidity assessment and reporting in a multiinstitutional international context: Insights from the EMBRACE studies on cervical cancer. Kirchheiner K, Smet S, Spampinato S, Jensen NBK, Vittrup AS, Fokdal L, Najjari-Jamal D, Westerveld HG, Lindegaard JC, Kirisits C, De Leeuw A, Schmid MP, Tan LT, Nout RA, Jürgenliemk-Schulz IM, Pötter R, Tanderup K; EMBRACE Collaborative Group.Brachytherapy. 2020 Nov-Dec;19(6):837-849. oi:10.1016/j.brachy.2020.08.011. Epub 2020 Sep 22.PMID: 32978080 Review.
Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. Vittrup AS, Tanderup K, Bentzen SM, Jensen NBK, Spampinato S, Fokdal LU, Lindegaard JC, Sturdza A, Schmid M, Segedin B, Jürgenliemk-Schulz IM, Bruheim K, Mahantshetty U, Haie-Meder C, Rai B, Cooper R, van der Steen-Banasik E, Sundset M, Huang F, Nout RA, Villafranca E, Van Limbergen E, Pieters BR, Tan LT, Lutgens LCHW, Hoskin P, Pötter R, Kirchheiner K; EMBRACE Collaborative Group.
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):161-173. doi: 10.1016/j.ijrobp.2020.08.044. Epub 2020 Aug 25.PMID: 32853710
Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer.
Tanderup K, Nesvacil N, Kirchheiner K, Serban M, Spampinato S, Jensen NBK, Schmid M, Smet S, Westerveld H, Ecker S, Mahantshetty U, Swamidas J, Chopra S, Nout R, Tan LT, Fokdal L, Sturdza A, Jürgenliemk-Schulz I, de Leeuw A, Lindegaard JC, Kirisits C, Pötter R.Semin Radiat Oncol. 2020 Oct;30(4):311-327. doi: 10.1016/j.semradonc.2020.05.008.PMID: 32828387 Review.
Education and training for image-guided adaptive brachytherapy for cervix cancer-The (GEC)-ESTRO/EMBRACE perspective. Tan LT, Tanderup K, Kirisits C, Mahantshetty U, Swamidas J, Jürgenliemk-Schulz I, Lindegaard J, de Leeuw A, Nesvacil N, Assenholt M, Berger D, Diendorfer T, Dimopoulos J, Duke S, Ecker S, Fokdal L, Hellebust T, Jensen N, Kirchheiner K, Nout R, Petric P, Schmid M, Seppenwoolde Y, Sturdza A, Van Limbergen E, Haie-Meder C, Pötter R.Brachytherapy. 2020 Nov-Dec;19(6):827-836. doi: 10.1016/j.brachy.2020.06.012. Epub 2020 Aug 16.PMID: 32811761 Review.
Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study. Knoth J, Pötter R, Jürgenliemk-Schulz IM, Haie-Meder C, Fokdal L, Sturdza A, Hoskin P, Mahantshetty U, Segedin B, Bruheim K, Wiebe E, Rai B, Cooper R, van der Steen-Banasik E, van Limbergen E, Pieters BR, Sundset M, Tan LT, Nout RA, Tanderup K, Kirisits C, Nesvacil N, Lindegaard JC, Schmid MP.Gynecol Oncol. 2020 Oct;159(1):136-141. doi: 10.1016/j.ygyno.2020.07.007. Epub 2020 Aug 11.PMID: 32798000
Hybrid TRUS/CT with optical tracking for target delineation in image-guided adaptive brachytherapy for cervical cancer. Smet S, Nesvacil N, Knoth J, Sturdza A, Najjari-Jamal D, Jelinek F, Kronreif G, Pötter R, Widder J, Kirisits C, Schmid MP.Strahlenther Onkol. 2020 Nov;196(11):983-992. doi: 10.1007/s00066-020-01656-2. Epub 2020 Jul 3.PMID: 32621011 Free PMC article.
GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy.
Siebert FA, Kirisits C, Hellebust TP, Baltas D, Verhaegen F, Camps S, Pieters B, Kovács G, Thomadsen B.
Radiother Oncol. 2020 Jul;148:51-56. doi: 10.1016/j.radonc.2020.02.024. Epub 2020 Mar 30.PMID: 32335363
Implementing an online radiotherapy quality assurance programme with supporting continuous medical education - report from the EMBRACE-II evaluation of cervix cancer IMRT contouring.
Duke SL, Tan LT, Jensen NBK, Rumpold T, De Leeuw AAC, Kirisits C, Lindegaard JC, Tanderup K, Pötter RC, Nout RA, Jürgenliemk-Schulz IM.Radiother Oncol. 2020 Jun;147:22-29. doi: 0.1016/j.radonc.2020.02.017. Epub 2020 Mar 30.PMID: 32240907
Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer.
Westerveld H, Nesvacil N, Fokdal L, Chargari C, Schmid MP, Milosevic M, Mahantshetty UM, Nout RA.
Lancet Oncol. 2020 Mar;21(3):e157-e167. doi: 10.1016/S1470-2045(19)30855-1.PMID: 32135119 Review.
Dose planning variations related to delineation variations in MRI-guided brachytherapy for locally advanced cervical cancer. Bell L, Holloway L, Bruheim K, Petrič P, Kirisits C, Tanderup K, Pötter R, Vinod S, Lim K, Pogson E, Metcalfe P, Hellebust TP.
Brachytherapy. 2020 Mar-Apr;19(2):146-153. doi: 10.1016/j.brachy.2020.01.002. Epub 2020 Feb 14.
PMID: 32067884
Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome. Mahantshetty U, Sturdza A, Naga Ch P, Berger D, Fortin I, Motisi L, Schmid MP, Aravindakshan D, Ghadi Y, Swamidas JV, Chopra S, Gurram L, Nesvacil N, Kirisits C, Pötter R.Radiother Oncol. 2019 Dec;141:123-129. doi: 0.1016/j.radonc.2019.08.004. Epub 2019 Sep 5.PMID: 31495516
Kreuzinger, C., von der Decken, I., Wolf, A., Gamperl, M., Koller, J., Karacs, J., Pfaffinger, S., Bartl, T., Reinthaller, A., Grimm, C., Singer, C. F., Braicu, E. I., Cunnea, P., Gourley, C., Smeets, D., Boeckx, B., Lambrechts, D., Perco, P., Horvat, R., Berns, E. M. J. J., … Cacsire Castillo-Tong, D. (2019). Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. Cancer letters, 459, 1–12. https://doi.org/10.1016/j.canlet.2019.05.032
Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery.Bekos C, Polterauer S, Seebacher V, Bartl T, Joura E, Reinthaller A, Sturdza A, Horvat R, Schwameis R, Grimm C.Arch Gynecol Obstet. 2019 Oct;300(4):1015-1022. doi: 10.1007/s00404-019-05278-7. Epub 2019 Aug 29.PMID: 31468203 Free PMC article.
Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Nomden CN, Pötter R, de Leeuw AAC, Tanderup K, Lindegaard JC, Schmid MP, Fortin I, Haie-Meder C, Mahantshetty U, Hoskin P, Segedin B, Bruheim K, Rai B, Huang F, Cooper R, Van Der Steen Banasik E, Van Limbergen E, Jürgenliemk-Schulz IM; EMBRACE Collaborative Group.
Radiother Oncol. 2019 May;134:185-190. doi: 10.1016/j.radonc.2019.02.007. Epub 2019 Feb 26.
PMID: 31005214
Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. Tan LT, Pötter R, Sturdza A, Fokdal L, Haie-Meder C, Schmid M, Gregory D, Petric P, Jürgenliemk-Schulz I, Gillham C, Van Limbergen E, Hoskin P, Tharavichitkul E, Villafranca E, Mahantshetty U, Kirisits C, Lindegaard J, Kirchheiner K, Tanderup K.Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):895-902. doi: 10.1016/j.ijrobp.2019.03.038. Epub 2019 Mar 30.PMID: 30940530
Importance of training in external beam treatment planning for locally advanced cervix cancer: Report from the EMBRACE II dummy run. Seppenwoolde Y, Assenholt MS, Georg D, Nout R, Tan LT, Rumpold T, de Leeuw A, Jürgenliemk-Schulz I, Kirisits C, Pötter R, Lindegaard JC, Tanderup K; EMBRACE Collaborative Group.Radiother Oncol. 2019 Apr;133:149-155. doi: 10.1016/j.radonc.2019.01.012. Epub 2019 Jan 28.
PMID: 30935571
Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II.
Berger T, Seppenwoolde Y, Pötter R, Assenholt MS, Lindegaard JC, Nout RA, de Leeuw A, Jürgenliemk-Schulz I, Tan LT, Georg D, Kirisits C, Dumas I, Nesvacil N, Swamidas J, Hudej R, Lowe G, Hellebust TP, Menon G, Fokdal L, Tanderup K; EMBRACE Collaborative Group.Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):885-894. doi: 10.1016/j.ijrobp.2019.03.020. Epub 2019 Mar 21.
PMID: 30904706 Clinical Trial.
Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. Fokdal L, Tanderup K, Pötter R, Sturdza A, Kirchheiner K, Chargari C, Jürgenliemk-Schulz IM, Segedin B, Tan LT, Hoskin P, Mahantshetty U, Bruheim K, Rai B, Kirisits C, Lindegaard JC; EMBRACE Collaborative Group.Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):887-894. doi: 10.1016/j.ijrobp.2018.11.006. Epub 2018 Nov 10.
PMID: 30419309
Prolapse surgery versus vaginal pessary in women with symptomatic pelvic organ prolapse: which factors influence the choice of treatment? Bodner-Adler B, Bodner K, Stinglmeier A, Kimberger O, Halpern K, Koelbl H, Umek W. Arch Gynecol Obstet. 2019 Mar;299(3):773-777. doi: 10.1007/s00404-019-05046-7. Epub 2019 Jan 17. PMID: 30656443 Free PMC article.
Genetic association in female stress urinary incontinence based on proteomic findings: a case-control study. Reischer T, Balendran-Braun S, Liebmann-Reindl S, Streubel B, Umek W, Koelbl H, Koch M. Int Urogynecol J. 2020 Jan;31(1):117-122. doi: 10.1007/s00192-019-03878-0. Epub 2019 Feb 4. PMID: 30715578 Free PMC article.
Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S. Gynecol Oncol. 2019 May;153(2):286-291. doi: 10.1016/j.ygyno.2019.02.007. Epub 2019 Feb 11. PMID: 30760408
The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Poetsch N, Sturdza A, Aust S, Polterauer S, Grimm C, Schwameis R, Pötter R, Koelbl H, Reinthaller A, Seebacher V. Strahlenther Onkol. 2019 May;195(5):430-440. doi: 10.1007/s00066-019-01430-z. Epub 2019 Feb 8. PMID: 30737542 Free PMC article.
Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology. Bjelic-Radisic V, Singer C, Tamussino K, Kölbl H, Petru E, Volgger B, Polterauer S, Oppelt P, Sevelda P, Bogner G, Marth C; Austrian Gynecologic Oncology Working Group. Wien Klin Wochenschr. 2019 May;131(9-10):233-236. doi: 10.1007/s00508-019-1468-7. Epub 2019 Mar 18. PMID: 30887224
Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex. Chapple CR, Mironska E, Wagg A, Milsom I, Diaz DC, Koelbl H, Pushkar D, Tubaro A, De Ridder D, Chartier-Kastler E, Phillips LD. Eur Urol Focus. 2020 May 15;6(3):522-530. doi: 10.1016/j.euf.2019.09.020. Epub 2019 Oct 15. PMID: 31623981 Review.
Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy.
Danzinger S, Köstler WJ, Funovics M, Herac M, Müllauer L, Prosch H, Kölbl H. Case Rep Obstet Gynecol. 2019 Jun 12;2019:9461579. doi: 10.1155/2019/9461579. eCollection 2019. PMID: 31281696 Free PMC article
The ESGO-EFC position paper of the European Society of Gynecologic Oncology and the European Federation of Colposcopy. Joura EA, Kyrgiou M, Bosch FX, Kesic V, Niemenen P, Redman C, Gültekin M. The ESGO-EFC position paper of the European Society of Gynecologic Oncology and the European Federation of ColposcopyEur J Cancer 2019; 116:21-6. ***,IF 7,191
Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery. Bekos C, Polterauer S, Seebacher V, Bartl T, Joura E, Reinthaller A, Sturdza A, Horvat R, Schwameis R, Grimm C. Arch Gynecol Obstet 2019;300:1015-22. *,IF 2,199
Vulvar, Penile and Scrotal Human Papillomavirus and non-Human Papillomavirus Cancer Pathways.Joura E, Jenkins D, Guimera N. Vulvar, Penile and Scrotal Human Papillomavirus and non-Human Papillomavirus Cancer Pathways. In: Jenkins D, Bosch FX (eds.) Human Papillomavirus- proving and using viral cause for cancer. Academic Press (Elsevier), London 2019
HPV vaccination and recurrent disease after conization: a meta-analysis (P41) V Paspalj, R Schwameis, S Pils, R Ristl, E Joura Int J Gynecol Cancer 2019, 29 (Suppl 4)
The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study. Gensthaler L, Joura EA, Alemany L, Horvat R, de Sanjose S, Pils S. Arch Gynecol Obstet 2020;301:753-9 *,IF 2,199
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Ferris DG, Brown D, Giuliano AR, Myers E, Joura EA, Garland SM, Kjaer SK, Perez G, Saah A, Luxembourg A. Papillomavirus Res 2020;10:100202
Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age Moreira E, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A.. Hum Vacc Immunother
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, Van Damme P, Bosch XHum Vacc Immunother 2018;14:1800-6*, IF: 2,157
Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Bekos C, Schwameis R, Heinze G, Gärner M, Grimm C, Joura E, Horvat R, Polterauer S, Polterauer M.
Sci Rep 2018;8:6383 **, IF: 4,122
SPERANZA project: HPV vaccination after treatment for CIN2+. Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, Svelato A, Lombardi S, Bertacca G, Joura EA.
Gynecol Oncol 2018;151:229-34 ***, IF: 4,540
9-valent HPV vaccine efficacy against related diseases and definitive therapy: Comparison with historic placebo population.Giuliano AR, Joura EA, Garland SM, Huh W, Iversen OE, Kjaer SK, Ferenczy A, Stoler MH, Bautista OM, Moeller E, Ritter M, Shields C, Luxembourg A. 9-valent HPV vaccine efficacy against related diseases and definitive therapy: Comparison with historic placebo population.Gynecol Oncol 2019;154:110-7 ***, IF: 4,540
A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. Grimm C, Polterauer S, Helmy-Bader S, Zikan M, Cibula D, Heitz F, Harter P, Giese A, Reinthaller A, Tempfer C. Gynecol Oncol. 2018 Jan 30. IF: 4.959
A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. Grimm C, Polterauer S, Helmy-Bader S, Zikan M, Cibula D, Heitz F, Harter P, Giese A, Reinthaller A, Tempfer C. Gynecol Oncol. 2018 Jan 30. IF: 4.959
Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. Int J Gynecol Cancer. Maritschnegg E, Heitz F, Pecha N, Bouda J, Trillsch F, Grimm C, Vanderstichele A, Agreiter C, Harter P, Obermayr E, Vergote I, Zeillinger R, Speiser P. 2018 Nov;28(9):1692-1698. IF: 1.932
Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data. Kranawetter M, Röhrich S, Müllauer L, Obermair H, Reinthaller A, Grimm C, Sturdza A, Köstler WJ, Polterauer S. Int J Gynecol Cancer. 2018 Jul;28(6):1196-1202. IF:1.932
Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.Bartl T, Schwameis R, Stift A, Bachleitner-Hofmann T, Reinthaller A, Grimm C, Polterauer S. Int J Gynecol Cancer. 2018 Nov;28(9):1664-1671. IF: 1.932
M. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Bekos C, Schwameis R, Heinze G, Gärner M, Grimm C, Joura E, Horvat R, Polterauer S, Sci Rep. 2018 Apr 23;8(1):6383. IF: 5.228
Influence of training level on cervical cone size and resection margin status at conization: a retrospective study. Montanari E, Grimm C, Schwameis R, Kuessel L, Polterauer S, Paternostro C, Husslein H. Arch Gynecol Obstet. 2018 Jun;297(6):1517-1523. IF: 1.364
Prognostic value of preoperative hyponatremia and thrombocytosis in patients with epithelial ovarian cancer. Hefler-Frischmuth K, Grimm C, Gensthaler L, Reiser E, Schwameis R, Hefler LA. Wien Klin Wochenschr. 2018 Oct;130(19-20):575-580. IF: 0.791
Prognostic Value of Serum Creatinine Levels in Patients with Epithelial Ovarian Cancer. Lafleur J, Hefler-Frischmuth K, Grimm C, Schwameis R, Gensthaler L, Reiser E, Hefler LAAnticancer Res. 2018 Sep;38(9):5127-5130. IF: 1.390
Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score. Seebacher V, Sturdza A, Bergmeister B, Polterauer S, Grimm C, Reinthaller A, Hilal Z, Aust S. Arch Gynecol Obstet. 2018 Dec 10.IF: 1.364
Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast. Marhold M, Tomasich E, Schwarz M, Udovica S, Heinzel A, Mayer P, Horak P, Perco P, Krainer M (2018). Oncotarget - 9(91):36379-36391
Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells.Obermayr, E., Maritschnegg, E., Agreiter, C., Pecha, N., Speiser, P., Helmy-Bader, S., Danzinger, S., Krainer, M., Singer,C., Zeillinger, R., (2017) – Oncotarget - 9(1):812-823. doi: 10.18632/oncotarget.22549. ePub 2018 Jan 2.
Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer. Bartl T, Schwameis R, Stift A, Bachleitner-Hofmann T, Reinthaller A, Grimm C, Polterauer S.Int J Gynecol Cancer. 2018 Nov;28(9):1664-1671. doi:10.1097/IGC.0000000000001369.
A POLYMER LIGAND-BASED ELISA FOR ROBUST, HIGH-THROUGHPUT, QUANTITATIVE DETECTION OF P53 AGGREGATES.Maritschnegg E, Heinzl N, Wilson S, Deycmar S, Niebuhr M, Klameth L, Holzer B, Koziel K, Concin N, Zeillinger R. Anal Chem.; 2018 Nov 20; 90(22):13273-13279
UTERINE AND TUBAL LAVAGE FOR EARLIER CANCER DETECTION USING AN INNOVATIVE CATHETER: A FEASIBILITY AND SAFETY STUDY.. Maritschnegg E, Heitz F, Pecha N, Bouda J, Trillsch F, Grimm C, Vanderstichele A, Agreiter C, Harter P, Obermayr E, Vergote I, Zeillinger R, Speiser P. Int J Gynecol Cancer; 2018 Nov 28(9):1692-1698
CLINICAL SIGNIFICANCE OF ORGANIC ANION TRANSPORTING POLYPEPTIDE GENE EXPRESSION IN HIGH-GRADE SEROUS OVARIAN CANCER. Svoboda M, Mungenast F, Gleiss A, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Jäger W, Mechtcheriakova D, Cacsire-Tong D, Zeillinger R, Thalhamer T, Pils D. Front Pharmacol.; 2018 Aug 7 (9):842
CORRECTION: DIAGNOSTIC MARKERS FOR THE DETECTION OF OVARIAN CANCER IN BRCA1 MUTATION CARRIERS. Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF. PLoS One; 2018 Apr 17; 13(4):e0196142
IMMUNOBIOCHEMICAL PATHWAYS OF NEOPTERIN FORMATION AND TRYPTOPHAN BREAKDOWN VIA INDOLEAMINE 2,3-DIOXYGENASE CORRELATE WITH CIRCULATING TUMOR CELLS IN OVARIAN CANCER PATIENTS – A STUDY OF THE OVCAD CONSORTIUM. Gostner JM, Obermayr E, Braicu IE, Concin N, Mahner S, Vanderstichele A, Sehouli J, Vergote I, Fuchs D, Zeillinger R. Gynecol Oncol.; 2018 May; 149(2):371-380.
EFFICIENT LEUKOCYTE DEPLETION BY A NOVEL MICROFLUIDIC PLATFORM ENABLES THE MOLECULAR DETECTION AND CHARACTERIZATION OF CIRCULATING TUMOR CELLS. Obermayr E, Maritschnegg E, Agreiter C, Pecha N, Speiser P, Helmy-Bader S, Danzinger S, Krainer M, Singer C, Zeillinger R. Oncotarget; 2017 Nov 28; 9(1):812-823
Treatment of Cervicofacial Lymphaticovenous Malformation with Vascularized Lymph Node Transfer. Roka-Palkovits J, Steinbacher J, Tinhofer I, Pona I, Matzek WK, Staudenherz A, Rath T, Radtke C, Weninger W, Tzou CJ. Plast Reconstr Surg. 2018 Sep;142(3):425e-426e. doi: 10.1097/PRS.0000000000004628
Assessing the kidney function parameters glomerular filtration rate and effective renal plasma flow with dynamic FDG-PET/MRI in healthy subjects. Geist BK, Baltzer P, Fueger B, Hamboeck M, Nakuz T, Papp L, Rasul S, Sundar LKS, Hacker M, Staudenherz A. EJNMMI Res. 2018 May 9;8(1):37. doi: 10.1186/s13550-018-0389-1.
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Böhmig GA. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14.
Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18 F]FDG-PET imaging. Is it of value in asymptomatic patients?Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, Aszmann O, Hojreh A, Peyrl A, Amann G, Benkoe TM, Wadsak W, Kasprian G, Staudenherz A, Hacker M, Traub-Weidinger T. Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26733. Epub 2017 Aug 3.
Association of endogenous circulating sex steroids and condition-specific quality of life domains in postmenopausal women with pelvic floor disorders. Bodner-Adler B, Bodner K, Kimberger O, Halpern K, Koelbl H, Umek W. Arch Gynecol Obstet. 2018 Mar;297(3):725-730. doi: 10.1007/s00404-018-4650-7. Epub 2018 Jan 15
AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer - a retrospective multi-centre study. Seebacher V, Polterauer S, Reinthaller A, Koelbl H, Achleitner R, Berger A, Concin N. BMC Cancer. 2018 Apr 19;18(1):447. doi: 10.1186/s12885-018-4289-6.
»Serum proteomic pattern in female stress urinary incontinence. Koch M, Umek W, Hanzal E, Mohr T, Seyfert S, Koelbl H, Mitulović G.Electrophoresis. 2018 Apr;39(8):1071-1078. doi: 10.1002/elps.201700423. Epub 2018 Feb 6.
Association of uterine leiomyoma and overactive bladder syndrome. Koch M, Rauchenwald T, Kivaranovic D, Schwab S, Umek W, Koelbl H, Rauchenwald M, Helmy S. Int J Gynaecol Obstet. 2018 Sep;142(3):365-369. doi: 10.1002/ijgo.12545. Epub 2018 Jun 28.
Co-expressed genes enhance precision of receptor status identification in breast cancer patients. Kenn M, Cacsire Castillo-Tong D, Singer CF, Cibena M, Kölbl H, Schreiner W.Breast Cancer Res Treat. 2018 Nov;172(2):313-326. doi: 10.1007/s10549-018-4920-x. Epub 2018 Aug 16.
Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory.Reich O, Braune G, Eppel W, Fiedler T, Graf A, Hefler L, Joura E, Kölbl H, Marth C, Pokieser W, Regitnig P, Reinthaller A, Tamussino K, Widschwendter A, Zeimet A, Kohlberger P.Geburtshilfe Frauenheilkd. 2018 Dec;78(12):1232-1244. doi: 10.1055/a-0764-4875. Epub 2018 Dec 14.
»Risk and protective factors for obstetric anal sphincter injuries: A retrospective nationwide study.Marschalek ML, Worda C, Kuessel L, Koelbl H, Oberaigner W, Leitner H, Marschalek J, Husslein H.Birth. 2018 Dec;45(4):409-415. doi: 10.1111/birt.12346. Epub 2018 Mar 14
Kreuzinger, C., Geroldinger, A., Smeets, D., Braicu, E. I., Sehouli, J., Koller, J., Wolf, A., Darb-Esfahani, S., Joehrens, K., Vergote, I., Vanderstichele, A., Boeckx, B., Lambrechts, D., Gabra, H., Wisman, G. B. A., Trillsch, F., Heinze, G., Horvat, R., Polterauer, S., Berns, E., … Cacsire Castillo-Tong, D. (2017). A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(24), 7621–7632. https://doi.org/10.1158/1078-0432.CCR-17-1159
Comparison of a prototype reverse hybridization assay and MethyLight for detection of SFRP2 promotor methylation in fecal DNA.Kriegshäuser G, Enko D, Zitt M, Oberwalder M, Oberkanins C, Öfner D, Zeillinger R, Maximilian Müller H.. Int J Biol Markers. 2017 Oct 31;32(4):e467-e470. doi: 10.5301/ijbm.5000289. PubMed PMID: 28777432.
Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance. Klameth L, Rath B, Hochmaier M, Moser D, Redl M, Mungenast F, Gelles K, Ulsperger E, Zeillinger R, Hamilton G. Sci Rep. 2017 Jul 13;7(1):5337. doi: 10.1038/s41598-017-05562-z. PubMed PMID: 28706293; PubMed Central PMCID: PMC5509650.
»Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin? Sukhbaatar N, Bachmayr-Heyda A, Auer K, Aust S, Deycmar S, Horvat R, Pils D. Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001461. doi: 10.1101/mcs.a001461. Print 2017 Jul. PubMed PMID: 28679689; PubMed Central PMCID:PMC5495036.
»EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. Dis Markers. Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, Pecha N, Mandorfer M, Pils D, Brisson AR, Zeillinger R, Lim SK.. 2017;2017:9653194. doi: 10.1155/2017/9653194. Epub 2017 May 16. PubMed PMID: 28607529; PubMed Central PMCID: PMC5451862.
»PARP inhibition causes premature loss of cohesion in cancer cells. Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D.Oncotarget. 2017 Oct 16;8(61):103931-103951. doi: 10.18632/oncotarget.21879. eCollection 2017 Nov 28. PubMed PMID: 29262611; PubMed Central PMCID: PMC5732777.
»Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget. Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong,DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C,Zeillinger R, Brandt B. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017Dec 5. PubMed PMID: 29290959; PubMed Central PMCID: PMC5739744.
»EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. Dis Markers. Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, Pecha N, Mandorfer M, Pils D, Brisson AR, Zeillinger R, Lim SK.. 2017;2017:9653194. doi: 10.1155/2017/9653194. Epub 2017 May 16. PubMed PMID: 28607529; PubMed Central PMCID: PMC5451862.
Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, Zeillinger R, Thalhammer T. Oncol Lett. 2017 Jun;13(6):4047-4054. doi: 10.3892/ol.2017.5969. Epub 2017 Apr 3. PubMed PMID: 28588698; PubMed Central PMCID: PMC5452883.
Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Pavo N, Lukovic D, Zlabinger K, Zimba A, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Jan Ankersmit H, Giricz Z, Baranyai T, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M. Sci Rep. 2017 Mar 7;7:43958. doi: 10.1038/srep43958. PubMed PMID: 28266659; PubMed Central PMCID: PMC5339807.
T.Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N,Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E,Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE,Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN,Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi Cancer Res. 2017 Mar 15;77(6):1250-1260. doi:10.1158/0008-5472.CAN-16-2179. Review. PubMed PMID: 28254861.
Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary,with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Auer K, Bachmayr-Heyda A, Aust S, Grunt TW, Pils D. Cancer Lett. 2017 Mar 1;388:158-166. doi: 10.1016/j.canlet.2016.11.034. Epub 2016Dec 7. PubMed PMID: 27940126.
Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer.Bachmayr-Heyda A, Aust S, Auer K, Meier SM, Schmetterer KG, Dekan S, Gerner C, Pils D. Clin Cancer Res. 2017 Apr 15;23(8):2081-2092.doi: 10.1158/1078-0432.CCR-16-1647. Epub 2016 Oct 19. PubMed PMID: 27797973.
Immunogenicity, and safety of a nine-valent human papillomavirus vaccine in women aged 16-26 years: Final analyses of a randomised, double-blind trial
Huh W, Joura EA, Giuliano AR, IversenOE, Rosires Pereira de Andrade, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Alain Luxembourg A. Efficacy
Lancet 2017;390:2143-59
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analyses of five phase III clinical trials
Petersen LK, Restrepo J, Moreira ED, Iversen OE, Pitisuttithum P, Van Damme P, Joura EA, Olsson SE, Ferris D, Block S, Giuliano AR, Bosch X, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista O, Hyatt D, Maansson R, Moeller E, Qi H, Roberts C, Luxembourg A. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analyses of five phase III clinical trials.
Papillomavirus Res 2017;3:105-15
The Impact of Written Information and Counseling (WOMAN-PRO II Program) on Symptom Outcomes in Women with Vulvar Neoplasia: A Multicenter Randomized Controlled Phase II Study
Raphaelis S, Mayer H, Ott S, Mueller MD, Steiner E, Joura E, Senn B.
Gynecol Oncol 2017;146:114-22
Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine
Guevara A, Cabello R, Woelber L, Moreira ED, Joura E, Reich O, Shields C, Ellison M, Joshi A, Luxembourg
Vaccine 2017;35:5050-7
Safety profile of the 9-Valent HPV vaccine: A combined analysis of 7 Phase III clinical trials Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D,
Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A .
Pediatrics 2016; 138. pii: e20154387. ,IF: 5,8
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria Boiron L, Joura E, Largeron N, Prager B, Uhart M. BMC Infect Dis 2016;16:153. doi:10.1186/s12879-016-1483-5. , IF: 2, 17
Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines
Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Vaccine 2016;34:757-61. ,IF:3,624
Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients
Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Cacsire Castillo-Tong D, Wisman GB, Berns EM, Siddiqui N, Paul J, Brown R.
Clin Cancer Res. 2016 Sep 23. PMID: 27663594
Short-Term Efficacy of Trichloroacetic Acid in the Treatment of Cervical Intraepithelial Neoplasia
Geisler S, Speiser S, Speiser L, Heinze G, Rosenthal A, Speiser P. Obstet Gynecol. 2016 Feb;127(2):353-9.
Association of HER2 codon 655 polymorphism with ovarian cancer
Watrowski R, Castillo-Tong DC, Schuster E, Fischer MB, Speiser P, Zeillinger R. Tumour Biol. 2016 Jun;37(6):7239-44. doi: 10.1007/s13277-015-4609-2. PMID: 26666819
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote . Eur J Cancer. 2016 Jan;53:51-64. PMID: 26693899
Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype
Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R. Cell Adh Migr. 2016 Jul 3;10(4):360-7. PMID: 26919626
Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies
Kuessel L, Kasimir-Bauer S, Zeillinger R, Pateisky P, Ott J, Zeisler H, Birdir C. Hypertens Pregnancy. 2016 Aug; 35(3):323-9 PMID: 26930176
Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, VAN Nieuwenhuysen E, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI. Anticancer Res. 2016 Mar;36(3):1015-22. PMID: 26976992
Statistical controversies in clinical research: the importance of importance
Gleiss A, Zeillinger R, Braicu EI, Trillsch F, Vergote I, Schemper M.
Ann Oncol. 2016 Jul; 27(7):1185-9. PMID: 27052655
Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer"
[Eur J Cancer 53 (2016) 51-64]
Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Castillo-Tong DC, Lambrechts D, Vergote I. .Eur J Cancer. 2016 Jun; 60:226. PMID: 27106403
AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
Svoboda M, Meshcheryakova A, Heinze G, Jaritz M, Pils D, Castillo-Tong DC, Hager G, Thalhammer T, Jensen-Jarolim E, Birner P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Zimmermann P, Zeillinger R, Mechtcheriakova D. BMC Genomics. 2016 Aug 16; 17(1):643. PMID:
27527602
Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors
Watrowski R, Heinze G, Jäger C, Forster J, Zeillinger R.
Tumour Biol. 2016 Sep; 37(9):12079-12087. PMID: 27207344
Effect of Preoperative Warm-up Exercise Before Laparoscopic Gynecological Surgery: A Randomized Trial
Polterauer S, Husslein H, Kranawetter M, Schwameis R, Reinthaller A, Heinze G, Grimm C. J Surg Educ. 2016 May-Jun;73(3):429-32. PMID: 26778744
Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015)
Tempfer C, Horn LC, Ackermann S, Beckmann MW, Dittrich R, Einenkel J, Günthert A, Haase H, Kratzsch J, Kreissl MC, Polterauer S, Ebert AD, Schneider KT, Strauss HG, Thiel F. Geburtshilfe Frauenheilkd. 2016 Feb;76(2):134-144. PMID: 26941444
»Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature
Mailath-Pokorny M, Schwameis R, Grimm C, Reinthaller A, Polterauer S. BMC Pregnancy Childbirth. 2016 Apr 7;16:74. PMID: 27055819
Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study
Pinker K, Andrzejewski P, Baltzer P, Polanec SH, Sturdza A, Georg D, Helbich TH, Karanikas G, Grimm C, Polterauer S, Poetter R, Wadsak W, Mitterhauser M, Georg P. PLoS One. 2016 May 11;11(5). PMID: 27167829
Risk Factors for De Novo Malignancies in Women After Kidney Transplantation: A Multicenter Transversal Study
Helmy S, Marschalek J, Bader Y, Koch M, Schmidt A, Kanzler M, Gyoeri G, Polterauer S, Reinthaller A, Grimm C. Int J Gynecol Cancer. 2016 Jun;26(5):967-70. PMID: 27206219
The prognostic role of metformin in patients with endometrial cancer: a retrospective study Seebacher V, Bergmeister B, Grimm C, Koelbl H, Reinthaller A, Polterauer S. Eur J Obstet Gynecol Reprod Biol. 2016 Aug;203:291-6. PMID: 27423029
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid
Zeitlinger M, Schwameis R, Burian A, Burian B, Matzneller P, Müller M, Wicha WW, Strickmann DB, Prince W. . J Antimicrob Chemother. 2016
Apr;71(4):1022-6. PMID:26747098
Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo- Controlled Trial
Schwameis R, Pils S, Weber M, Hagmann M, Zeitlinger M, Sauermann R.
Pharmacology. 2016; 98(1-2):93-8. PMID: 27165542
Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma Schwameis R, Grimm C, Brodowicz T, Petru E, Hefler-Frischmuth K, Staudigl C, Reinthaller A, Heinze G, Polterauer S, Polterauer M. Sci Rep. 2016 Sep 20;6: 33757. PMID: 27646551
Training on an inexpensive tablet-based device is equally effective as on a standard laparoscopic box trainer: A randomized controlled trial
Montanari E, Schwameis R, Louridas M, Göbl C, Kuessel L, Polterauer S, Husslein H. Medicine (Baltimore). 2016 Sep; 95(39):e4826.PMID:27684813
Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV
Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S, du Bois A. Gynecol Oncol. 2016 Feb;140(2):215-20. PMID: 26691222
Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer Prader S, Harter P, Grimm C, Traut A, Waltering KU, Alesina PF, Heikaus S, Ataseven B, Heitz F, Schneider S, du Bois A. Gynecol Oncol. 2016 May; 141(2):271-5 PMID: 26972337
Risk Factors for De Novo Malignancies in Women After Kidney Transplantation: A Multicenter Transversal Study
Helmy S, Marschalek J, Bader Y, Koch M, Schmidt A, Kanzler M, Gyoeri G, Polterauer S, Reinthaller A, Grimm C. Int J Gynecol Cancer. 2016 Jun; 26(5):967-70. PMID: 27206219
The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
Ataseven B, Harter P, Grimm C, Heitz F, Heikaus S, Traut A, Kahl A, Kurzeder C, Prader S, du Bois A. Gynecol Oncol. 2016 Aug;142(2):243-7. PMID: 27208538
Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer
Ataseven B, Grimm C, Harter P, Heikaus S, Heitz F, Traut A, Prader S, Kahl A, Schneider S, Kurzeder C, du Bois A. Ann Surg Oncol. 2016 Jul 12. [Epub ahead of print] PMID: 27406097
Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer
Ataseven B, du Bois A, Harter P, Prader S, Grimm C, Kurzeder C, Schneider S, Heikaus S, Kahl A, Traut A, Heitz F. Int J Gynecol Cancer. 2016 Nov; 26(9):1594-1600. PMID: 27654263
Role of the immune system in the peritoneal tumor spread of high grade serous
Auer K, Bachmayr-Heyda A, Sukhbaatar N, Aust S, Schmetterer KG, Meier SM, Gerner C, Grimm C, Horvat R, Pils D. ovarian cancer. Oncotarget. 2016 Aug 3:61336-61354.PMID: 27665539
Small RNAs and the competing endogenous RNA network in high grade serous ovarian Bachmayr-Heyda A, Auer K, Sukhbaatar N, Aust S, Deycmar S, Reiner AT, Polterauer S, Dekan S, Pils D. cancer tumor spread. Oncotarget. 2016 Jun 28;7(26):39640-39653.PMID: 27172797
Antiangiogenic therapies in ovarian cancer
Reinthaller A.. 2016;9(3):139-143. Review.
PMID:27752291
Topotecan plus carboplatin versus standard therapy with paclitaxel
plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
Canzler U, Mahner S, Meier W.
Ann Oncol. 2016 Oct 26. pii: mdw418. [Epub ahead of print] PMID:27789470
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study
Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W,
Angleitner-Boubenizek L, Brandt B, Chekerov R.
Br J Cancer. 2014 Sep 16. doi: 10.1038/bjc.2014.443.
[Epub ahead of print] PubMed PMID: 25225907.
A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial
Grimm C, Polterauer S, Helmy S, Cibula D, Zikan M, Reinthaller A, Tempfer C.
BMC Cancer. 2014 Aug 30;14:635. doi: 10.1186/1471-2407-14-635.
PubMed PMID: 25175029; PubMed Central PMCID: PMC4156659.
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall
M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M,
Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.
J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669.
Epub 2013 Dec 23. PubMed PMID: 24366937.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E,
Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I,
Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011.
Epub 2013 Oct 28. PubMed PMID: 24176298.
The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer
Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L, PolterauerS.
Eur J Obstet Gynecol Reprod Biol. 2013 Nov;171(1):101-6. doi:10.1016/j.ejogrb.2013.07.044. Epub 2013 Aug 11.
PubMed PMID: 24011381.
Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G,
Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S.
Br J Cancer. 2013 Aug 6;109(3):610-4. doi: 10.1038/bjc.2013.323.
Epub 2013 Jul 16. PubMed PMID: 23921280; PubMed Central PMCID: PMC3738124.
Association of myeloperoxidase with ovarian cancer
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A,
Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.
Tumour Biol. 2014 Jan;35(1):141-8. doi:10.1007/s13277-013-1017-3.
Epub 2013 Jul 27. PubMed PMID: 23893381; PubMed Central PMCID: PMC4039294.
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation
Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA,
Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.
J Natl Cancer Inst. 2013 Aug7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763. PubMed PMID: 23781004.
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial
Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R,
Taucher S, Wagener A, Marth C, Concin N.
Br J Cancer. 2013 Jul 9;109(1):215-8. doi: 10.1038/bjc.2013.282.
Epub 2013 Jun 13. PubMed PMID: 23764750; PubMed Central PMCID: PMC3708572.
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.
Gynecol Oncol. 2013 Aug;130(2):289-94. doi: 10.1016/j.ygyno.2013.05.013.
Epub 2013 May 18. PubMed PMID: 23694718.
Impact of conization type on the resected cone volume: results of a
retrospective multi-center study
Grimm C, Brammen L, Sliutz G, Weigert M, Sevelda P, Pils S, Reinthaller A,
Polterauer S.
Arch Gynecol Obstet. 2013 Nov;288(5):1081-6.
doi: 10.1007/s00404-013-2873-1. Epub 2013 May 7. PubMed PMID: 23649464.
The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser
P, Reinthaller A, Polterauer S.
BMC Cancer. 2013 Mar 14;13:115. doi: 10.1186/1471-2407-13-115.
PubMed PMID: 23497172; PubMed Central PMCID: PMC3605348.
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer
Aust S, Pils S, Polterauer S, Horvat R, Cacsire Castillo-Tong D, Pils D,
Dudek G, Schmid B, Speiser P, Reinthaller A, Grimm C.
Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):518-24.
doi: 10.1097/PAI.0b013e318284a053. PubMed PMID: 23455184.
HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium
Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S,
Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J.
Onco Targets Ther. 2014 Sep 11;7:1563-9. doi: 10.2147/OTT.S65373. eCollection 2014. PubMed PMID: 25246800; PubMed Central PMCID: PMC4166345.
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F,
Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N,
Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001.
Epub 2014 Jun 2. PubMed PMID: 24889916.
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium
Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S,
Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils
D.Mol Cancer. 2014 Mar 21;13:67. doi: 10.1186/1476-4598-13-67.
PubMed PMID: 24655477; PubMed Central PMCID: PMC3998046.
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma
Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C,
Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H,
Altevogt P.
Oncotarget 2014 Jan 30;5(2):462-72. PubMed PMID: 24497324;
PubMed Central PMCID: PMC3964221.
Association of TAP gene polymorphismsand risk of cervical intraepithelial neoplasia
Natter C, Polterauer S, Rahhal-Schupp J, Cacsire Castillo-Tong D, Pils S,
Speiser P, Zeillinger R, Heinze G, Grimm C.
Dis Markers. 2013;35(2):79-84. doi: 10.1155/2013/368732.
Epub 2013 Jul 28. PubMed PMID: 24288424; PubMed Central PMCID: PMC3774964
Known players, new interplay in atherogenesis: Chronic shear stress and carbamylated-LDL induce and modulateexpression of atherogenic LR11 in human coronary artery endothelium
Bajari TM, Winnicki W, Gensberger ET, Scharrer SI, Regele H, Aumayr K, Kopecky C, Gmeiner BM, Hermann M, Zeillinger R, Sengölge G.
Thromb Haemost. 2014 Feb;111(2):323-32. doi: 10.1160/TH12-12-0924.
Epub 2013 Nov 28. PubMed PMID: 24284991.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E,
Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I,
Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011.
Epub 2013 Oct 28. PubMed PMID: 24176298.
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium
Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli
J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.
BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422.
PubMed PMID: 24044611; PubMed Central PMCID: PMC3848589.
eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women
Groten T, Schleussner E, Lehmann T, Reister F, Holzer B, Danso KA, Zeillinger R.
Arch Gynecol Obstet. 2014 Mar;289(3):581-93. doi: 10.1007/s00404-013-2991-9.
Epub 2013 Sep 8. PubMed PMID: 24013430.
Association of myeloperoxidase with ovarian cancer
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A,
Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF
Tumour Biol. 2014 Jan;35(1):141-8. doi:10.1007/s13277-013-1017-3.
Epub 2013 Jul 27. PubMed PMID: 23893381; PubMed Central PMCID: PMC4039294.
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp
T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet
AG, Vergote I.
Gynecol Oncol. 2013 Oct;131(1):15-20. doi: 10.1016/j.ygyno.2013.07.086.
Epub 2013 Jul 20. PubMed PMID: 23877013.
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van
Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R,
Vergote I, Mahner S, Sehouli J.
J Ovarian Res. 2013 Jun 28;6(1):42. doi: 10.1186/1757-2215-6-42.
PubMed PMID: 23809664; PubMed Central PMCID: PMC3707788.
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium
Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E,
Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser
P, Zeillinger R.
BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.
PubMed PMID: 23551967; PubMed Central PMCID: PMC3639192.
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer
Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M,
Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC.
Int J Gynecol Pathol. 2013 May;32(3):269-76. doi: 10.1097/PGP.0b013e31826a63f8. PubMed PMID:23518910.
The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors
Secky L, Svoboda M, Klameth L, Bajna E, Hamilton G, Zeillinger R, Jäger W,
Thalhammer T.
J Drug Deliv.2013;2013:957605. doi: 10.1155/2013/957605.
Epub 2013 Feb 13. PubMed PMID: 23476785; PubMed Central PMCID: PMC3586502.
Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells
Vaňhara P, Horak P, Pils D, Anees M, Petz M, Gregor W, Zeillinger R, Krainer M.
Int J Oncol. 2013 Apr;42(4):1383-9. doi:10.3892/ijo.2013.1824.
Epub 2013 Feb 12. PubMed PMID: 23404293.
Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S,
Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 2013 Feb;23(2):268-75. doi: 10.1097/IGC.0b013e31827de6b9. PubMed PMID: 23358178.
Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens
Buxhofer-Ausch V, Ausch C, Zeillinger R, Oberkanins C, Dandachi N,
Reiner-Concin A, Kriegshäuser G.
Dis Markers. 2013;34(3):171-7. doi:10.3233/DMA-120960.
PubMed PMID: 23324583; PubMed Central PMCID: PMC3810114.
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study
Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H,
Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J.
Gynecol Oncol. 2013 Feb;128(2):245-51. doi: 10.1016/j.ygyno.2012.11.023.
Epub 2012 Nov 21. PubMed PMID: 23178313
Posttraumatic Stress Disorder After High-Dose-Rate Brachytherapy for Cervical Cancer With 2 Fractions in 1 Application Under Spinal/Epidural Anesthesia: Incidence and Risk Ractors.Kirchheiner K, Czajka-Pepl A, Ponocny-Seliger E, Scharbert G, Wetzel L, Nout RA, Sturdza A, Dimopoulos JC, Dörr W, Pötter R.
Int J Radiat Oncol Biol Phys. 2014 Apr 7.
Manifestation Pattern of Early-Late Vaginal Morbidity After Definitive Radiation (Chemo)Therapy and Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: An Analysis From the EMBRACE Study.
Kirchheiner K, Nout RA, Tanderup K, Lindegaard JC, Westerveld H, Haie-Meder C, Petrič P, Mahantshetty U, Dörr W, Pötter R. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):88-95.
Universal vaccination with the quadrivalent HPV vaccine in Austria: Impact on virus circulation, public health and cost-effectiveness analysis.
Bresse X, Goergen C, Prager B, Joura E.
Expert Rev Pharmacoecon Outcomes Res. 2014 Jan 22.
TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in vivo. Horak P, Tomasich E, Vanhara P, Kratochvílová K, Anees M, Marhold M, Lemberger CE, Gerschpacher M, Horvat R, Sibilia M, Pils D, Krainer M. Sci Rep. 2014 Jan 17;4:3739.
Association of myeloperoxidase with ovarian cancer.Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF. Tumour Biol. 2014 Jan;35(1):141-8.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110.
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P. Oncotarget. 2014 Jan 12.
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study.
Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.
J Clin Oncol. 2013 Dec 23.
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
Aust S, Pils S, Polterauer S, Horvat R, Cacsire Castillo-Tong D, Pils D, Dudek G, Schmid B, Speiser P, Reinthaller A, Grimm C.
Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):518-24.
Increase in ezrin expression from benign to malignant breast tumours.
Gschwantler-Kaulich D, Natter C, Steurer S, Walter I, Thomas A, Salama M, Singer CF.
Cell Oncol (Dordr). 2013 Dec;36(6):485-91.
The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer.
Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L, Polterauer S. Eur J Obstet Gynecol Reprod Biol. 2013 Nov;171(1):101-6.
Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM.
Kirisits C, Rivard MJ, Baltas D, Ballester F, De Brabandere M, van der Laarse R, Niatsetski Y, Papagiannis P, Hellebust TP, Perez-Calatayud J, Tanderup K, Venselaar JL, Siebert FA.
Radiother Oncol. 2013 Nov 30.
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva.
de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, Joura EA, Maldonado P, Laco J, Bravo IG, Vidal A, Guimerà N, Cross P, Wain GV, Petry KU, Mariani L, Bergeron C, Mandys V, Sica AR, Félix A, Usubutun A, Seoud M, Hernández-Suárez G, Nowakowski AM, Wilson G, Dalstein V, Hampl M, Kasamatsu ES, Lombardi LE, Tinoco L, Alvarado-Cabrero I, Perrotta M, Bhatla N, Agorastos T, Lynch CF, Goodman MT, Shin HR, Viarheichyk H, Jach R, Cruz MO, Velasco J, Molina C, Bornstein J, Ferrera A, Domingo EJ, Chou CY, Banjo AF, Castellsagué X, Pawlita M, Lloveras B, Quint WG, Muñoz N, Bosch FX; HPV VVAP study group.
Eur J Cancer. 2013 Nov;49(16):3450-61.
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study.
Rössler L, Reich O, Horvat R, de Souza SC, Holl K, Joura EA.
Wien Klin Wochenschr. 2013 Oct;125(19-20):591-9.
High-risk clinical target volume delineation in CT-guided cervical cancer brachytherapy: impact of information from FIGO stage with or without systematic inclusion of 3D documentation of clinical gynecological examination.
Hegazy N, Pötter R, Kirisits C, Berger D, Federico M, Sturdza A, Nesvacil N.
Acta Oncol. 2013 Oct;52(7):1345-52.
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.
Gynecol Oncol. 2013 Oct;131(1):15-20.
Association of TAP Gene Polymorphisms and Risk of Cervical Intraepithelial Neoplasia. Natter C, Polterauer S, Rahhal-Schupp J, Cacsire Castillo-Tong D, Pils S, Speiser P, Zeillinger R, Heinze G, Grimm C.
Dis Markers. 2013;35(2):79-84.
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.
BMC Cancer. 2013 Sep 17;13:422.
» L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.
J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50.
Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer.
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S.
Br J Cancer. 2013 Aug 6;109(3):610-4.
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.
Gynecol Oncol. 2013 Aug;130(2):289-94.
Single line source with and without vaginal loading and the impact on target coverage and organ at risk doses for cervix cancer Stages IB, II, and IIIB: treatment planning simulation in patients treated with MRI-guided adaptive brachytherapy in a multicentre study (EMBRACE).
Nkiwane KS, Pötter R, Tanderup K, Federico M, Lindegaard JC, Kirisits C.
Brachytherapy. 2013 Jul-Aug;12(4):317-23.
Association of myeloperoxidase with ovarian cancer.
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.
Tumor Biol. 2013 Jul 27.
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial.
Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R, Taucher S, Wagener A, Marth C, Concin N.
Br J Cancer. 2013 Jul 9;109(1):215-8.
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.
Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R, Vergote I, Mahner S, Sehouli J.
J Ovarian Res. 2013 Jun 28;6(1):42.
IL-24 sensitizes tumor cells to TLR3-mediated apoptosis.
Weiss R, Sachet M, Zinngrebe J, Aschacher T, Krainer M, Hegedus B, Walczak H, Bergmann M.
Cell Death Differ. 2013 Jun;20(6):823-33.
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer.
Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M, Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC.
Int J Gynecol Pathol. 2013 May;32(3):269-76.
Impact of conization type on the resected cone volume: results of a retrospective multi-center study.
Grimm C, Brammen L, Sliutz G, Weigert M, Sevelda P, Pils S, Reinthaller A, Polterauer S. Arch Gynecol Obstet. 2013 May 7.
A multicentre comparison of the dosimetric impact of inter- and intra-fractional anatomical variations in fractionated cervix cancer brachytherapy.
Nesvacil N, Tanderup K, Hellebust TP, De Leeuw A, Lang S, Mohamed S, Jamema SV, Anderson C, Pötter R, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):20-5.
Uncertainties in image guided adaptive cervix cancer brachytherapy: impact on planning and prescription.
Tanderup K, Nesvacil N, Pötter R, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):1-5.
Uncertainty analysis for 3D image-based cervix cancer brachytherapy by repetitive MR imaging: assessment of DVH-variations between two HDR fractions within one applicator insertion and their clinical relevance.
Lang S, Nesvacil N, Kirisits C, Georg P, Dimopoulos JC, Federico M, Pötter R.
Radiother Oncol. 2013 Apr;107(1):26-31.
Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytherapy.
Westerveld H, Pötter R, Berger D, Dankulchai P, Dörr W, Sora MC, Pötter-Lang S, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):99-105.
The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.
Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser P, Reinthaller A, Polterauer S.
BMC Cancer. 2013 Mar 14;13:115.
Methylation status of TUSC3 is a prognostic factor in ovarian cancer.
Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M.
Cancer. 2013 Mar 1;119(5):946-54.
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women.
Clark LR, Myers ER, Huh W, Joura EA, Paavonen J, Perez G, James MK, Sings HL, Haupt RM, Saah AJ, Garner EI. Clinical trial experience with prophylactic human papillomavirus 6/11/16/black women.
J Adolesc Health. 2013 Mar;52(3):322-9.
» Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 2013 Feb;23(2):268-75.
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K; HERACLES/SCALE Study Group.
Int J Cancer. 2013 Feb 15;132(4):854-67.
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.
Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R
Gynecol Oncol. 2013 Jan;128(1):15-21.
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: Results from the OVCAD study.
Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J.
Gynecol Oncol. 128:245-251, 2013.
Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.
Buxhofer-Ausch V, Ausch C, Zeillinger R, Oberkanins C, Dandachi N, Reiner-Concin A, Kriegshäuser G.
Dis Markers. 34(3):171-7, 2013.
Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 23(2):268-275, 2013.
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer-a study by the OVCAD consortium.
Melmer A, Fineder L, Lamina C, Kollerits B, Dieplinger B, Braicu I, Sehouli J, Cadron I, Vergote I, Mahner S, Zeimet AG, Castillo-Tong DC, Ebenbichler CF, Zeillinger R, Dieplinger H.
Gynecol Oncol. 128:38-43, 2013.
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.
BMC Cancer. 13:178, 2013.
Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.
Vaňhara P, Horak P, Pils D, Anees M, Petz M, Gregor W, Zeillinger R, Krainer M. Int J Oncol. 42(4):1383-9, 2013.
Kreuzinger, C., von der Decken, I., Wolf, A., Gamperl, M., Koller, J., Karacs, J., Pfaffinger, S., Bartl, T., Reinthaller, A., Grimm, C., Singer, C. F., Braicu, E. I., Cunnea, P., Gourley, C., Smeets, D., Boeckx, B., Lambrechts, D., Perco, P., Horvat, R., Berns, E. M. J. J., … Cacsire Castillo-Tong, D. (2019). Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. Cancer letters, 459, 1–12. https://doi.org/10.1016/j.canlet.2019.05.032
Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery.Bekos C, Polterauer S, Seebacher V, Bartl T, Joura E, Reinthaller A, Sturdza A, Horvat R, Schwameis R, Grimm C.Arch Gynecol Obstet. 2019 Oct;300(4):1015-1022. doi: 10.1007/s00404-019-05278-7. Epub 2019 Aug 29.PMID: 31468203 Free PMC article.
Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Nomden CN, Pötter R, de Leeuw AAC, Tanderup K, Lindegaard JC, Schmid MP, Fortin I, Haie-Meder C, Mahantshetty U, Hoskin P, Segedin B, Bruheim K, Rai B, Huang F, Cooper R, Van Der Steen Banasik E, Van Limbergen E, Jürgenliemk-Schulz IM; EMBRACE Collaborative Group.
Radiother Oncol. 2019 May;134:185-190. doi: 10.1016/j.radonc.2019.02.007. Epub 2019 Feb 26.
PMID: 31005214
Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. Tan LT, Pötter R, Sturdza A, Fokdal L, Haie-Meder C, Schmid M, Gregory D, Petric P, Jürgenliemk-Schulz I, Gillham C, Van Limbergen E, Hoskin P, Tharavichitkul E, Villafranca E, Mahantshetty U, Kirisits C, Lindegaard J, Kirchheiner K, Tanderup K.Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):895-902. doi: 10.1016/j.ijrobp.2019.03.038. Epub 2019 Mar 30.PMID: 30940530
Importance of training in external beam treatment planning for locally advanced cervix cancer: Report from the EMBRACE II dummy run. Seppenwoolde Y, Assenholt MS, Georg D, Nout R, Tan LT, Rumpold T, de Leeuw A, Jürgenliemk-Schulz I, Kirisits C, Pötter R, Lindegaard JC, Tanderup K; EMBRACE Collaborative Group.Radiother Oncol. 2019 Apr;133:149-155. doi: 10.1016/j.radonc.2019.01.012. Epub 2019 Jan 28.
PMID: 30935571
Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II.
Berger T, Seppenwoolde Y, Pötter R, Assenholt MS, Lindegaard JC, Nout RA, de Leeuw A, Jürgenliemk-Schulz I, Tan LT, Georg D, Kirisits C, Dumas I, Nesvacil N, Swamidas J, Hudej R, Lowe G, Hellebust TP, Menon G, Fokdal L, Tanderup K; EMBRACE Collaborative Group.Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):885-894. doi: 10.1016/j.ijrobp.2019.03.020. Epub 2019 Mar 21.
PMID: 30904706 Clinical Trial.
Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. Fokdal L, Tanderup K, Pötter R, Sturdza A, Kirchheiner K, Chargari C, Jürgenliemk-Schulz IM, Segedin B, Tan LT, Hoskin P, Mahantshetty U, Bruheim K, Rai B, Kirisits C, Lindegaard JC; EMBRACE Collaborative Group.Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):887-894. doi: 10.1016/j.ijrobp.2018.11.006. Epub 2018 Nov 10.
PMID: 30419309
Prolapse surgery versus vaginal pessary in women with symptomatic pelvic organ prolapse: which factors influence the choice of treatment? Bodner-Adler B, Bodner K, Stinglmeier A, Kimberger O, Halpern K, Koelbl H, Umek W. Arch Gynecol Obstet. 2019 Mar;299(3):773-777. doi: 10.1007/s00404-019-05046-7. Epub 2019 Jan 17. PMID: 30656443 Free PMC article.
Genetic association in female stress urinary incontinence based on proteomic findings: a case-control study. Reischer T, Balendran-Braun S, Liebmann-Reindl S, Streubel B, Umek W, Koelbl H, Koch M. Int Urogynecol J. 2020 Jan;31(1):117-122. doi: 10.1007/s00192-019-03878-0. Epub 2019 Feb 4. PMID: 30715578 Free PMC article.
Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S. Gynecol Oncol. 2019 May;153(2):286-291. doi: 10.1016/j.ygyno.2019.02.007. Epub 2019 Feb 11. PMID: 30760408
The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Poetsch N, Sturdza A, Aust S, Polterauer S, Grimm C, Schwameis R, Pötter R, Koelbl H, Reinthaller A, Seebacher V. Strahlenther Onkol. 2019 May;195(5):430-440. doi: 10.1007/s00066-019-01430-z. Epub 2019 Feb 8. PMID: 30737542 Free PMC article.
Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology. Bjelic-Radisic V, Singer C, Tamussino K, Kölbl H, Petru E, Volgger B, Polterauer S, Oppelt P, Sevelda P, Bogner G, Marth C; Austrian Gynecologic Oncology Working Group. Wien Klin Wochenschr. 2019 May;131(9-10):233-236. doi: 10.1007/s00508-019-1468-7. Epub 2019 Mar 18. PMID: 30887224
Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex. Chapple CR, Mironska E, Wagg A, Milsom I, Diaz DC, Koelbl H, Pushkar D, Tubaro A, De Ridder D, Chartier-Kastler E, Phillips LD. Eur Urol Focus. 2020 May 15;6(3):522-530. doi: 10.1016/j.euf.2019.09.020. Epub 2019 Oct 15. PMID: 31623981 Review.
Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy.
Danzinger S, Köstler WJ, Funovics M, Herac M, Müllauer L, Prosch H, Kölbl H. Case Rep Obstet Gynecol. 2019 Jun 12;2019:9461579. doi: 10.1155/2019/9461579. eCollection 2019. PMID: 31281696 Free PMC article
The ESGO-EFC position paper of the European Society of Gynecologic Oncology and the European Federation of Colposcopy. Joura EA, Kyrgiou M, Bosch FX, Kesic V, Niemenen P, Redman C, Gültekin M. The ESGO-EFC position paper of the European Society of Gynecologic Oncology and the European Federation of ColposcopyEur J Cancer 2019; 116:21-6. ***,IF 7,191
Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery. Bekos C, Polterauer S, Seebacher V, Bartl T, Joura E, Reinthaller A, Sturdza A, Horvat R, Schwameis R, Grimm C. Arch Gynecol Obstet 2019;300:1015-22. *,IF 2,199
Vulvar, Penile and Scrotal Human Papillomavirus and non-Human Papillomavirus Cancer Pathways.Joura E, Jenkins D, Guimera N. Vulvar, Penile and Scrotal Human Papillomavirus and non-Human Papillomavirus Cancer Pathways. In: Jenkins D, Bosch FX (eds.) Human Papillomavirus- proving and using viral cause for cancer. Academic Press (Elsevier), London 2019
HPV vaccination and recurrent disease after conization: a meta-analysis (P41) V Paspalj, R Schwameis, S Pils, R Ristl, E Joura Int J Gynecol Cancer 2019, 29 (Suppl 4)
The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study. Gensthaler L, Joura EA, Alemany L, Horvat R, de Sanjose S, Pils S. Arch Gynecol Obstet 2020;301:753-9 *,IF 2,199
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Ferris DG, Brown D, Giuliano AR, Myers E, Joura EA, Garland SM, Kjaer SK, Perez G, Saah A, Luxembourg A. Papillomavirus Res 2020;10:100202
Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age Moreira E, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A.. Hum Vacc Immunother
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, Van Damme P, Bosch XHum Vacc Immunother 2018;14:1800-6*, IF: 2,157
Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Bekos C, Schwameis R, Heinze G, Gärner M, Grimm C, Joura E, Horvat R, Polterauer S, Polterauer M.
Sci Rep 2018;8:6383 **, IF: 4,122
SPERANZA project: HPV vaccination after treatment for CIN2+. Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, Svelato A, Lombardi S, Bertacca G, Joura EA.
Gynecol Oncol 2018;151:229-34 ***, IF: 4,540
9-valent HPV vaccine efficacy against related diseases and definitive therapy: Comparison with historic placebo population.Giuliano AR, Joura EA, Garland SM, Huh W, Iversen OE, Kjaer SK, Ferenczy A, Stoler MH, Bautista OM, Moeller E, Ritter M, Shields C, Luxembourg A. 9-valent HPV vaccine efficacy against related diseases and definitive therapy: Comparison with historic placebo population.Gynecol Oncol 2019;154:110-7 ***, IF: 4,540
A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. Grimm C, Polterauer S, Helmy-Bader S, Zikan M, Cibula D, Heitz F, Harter P, Giese A, Reinthaller A, Tempfer C. Gynecol Oncol. 2018 Jan 30. IF: 4.959
A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. Grimm C, Polterauer S, Helmy-Bader S, Zikan M, Cibula D, Heitz F, Harter P, Giese A, Reinthaller A, Tempfer C. Gynecol Oncol. 2018 Jan 30. IF: 4.959
Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. Int J Gynecol Cancer. Maritschnegg E, Heitz F, Pecha N, Bouda J, Trillsch F, Grimm C, Vanderstichele A, Agreiter C, Harter P, Obermayr E, Vergote I, Zeillinger R, Speiser P. 2018 Nov;28(9):1692-1698. IF: 1.932
Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data. Kranawetter M, Röhrich S, Müllauer L, Obermair H, Reinthaller A, Grimm C, Sturdza A, Köstler WJ, Polterauer S. Int J Gynecol Cancer. 2018 Jul;28(6):1196-1202. IF:1.932
Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.Bartl T, Schwameis R, Stift A, Bachleitner-Hofmann T, Reinthaller A, Grimm C, Polterauer S. Int J Gynecol Cancer. 2018 Nov;28(9):1664-1671. IF: 1.932
M. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Bekos C, Schwameis R, Heinze G, Gärner M, Grimm C, Joura E, Horvat R, Polterauer S, Sci Rep. 2018 Apr 23;8(1):6383. IF: 5.228
Influence of training level on cervical cone size and resection margin status at conization: a retrospective study. Montanari E, Grimm C, Schwameis R, Kuessel L, Polterauer S, Paternostro C, Husslein H. Arch Gynecol Obstet. 2018 Jun;297(6):1517-1523. IF: 1.364
Prognostic value of preoperative hyponatremia and thrombocytosis in patients with epithelial ovarian cancer. Hefler-Frischmuth K, Grimm C, Gensthaler L, Reiser E, Schwameis R, Hefler LA. Wien Klin Wochenschr. 2018 Oct;130(19-20):575-580. IF: 0.791
Prognostic Value of Serum Creatinine Levels in Patients with Epithelial Ovarian Cancer. Lafleur J, Hefler-Frischmuth K, Grimm C, Schwameis R, Gensthaler L, Reiser E, Hefler LAAnticancer Res. 2018 Sep;38(9):5127-5130. IF: 1.390
Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score. Seebacher V, Sturdza A, Bergmeister B, Polterauer S, Grimm C, Reinthaller A, Hilal Z, Aust S. Arch Gynecol Obstet. 2018 Dec 10.IF: 1.364
Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast. Marhold M, Tomasich E, Schwarz M, Udovica S, Heinzel A, Mayer P, Horak P, Perco P, Krainer M (2018). Oncotarget - 9(91):36379-36391
Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells.Obermayr, E., Maritschnegg, E., Agreiter, C., Pecha, N., Speiser, P., Helmy-Bader, S., Danzinger, S., Krainer, M., Singer,C., Zeillinger, R., (2017) – Oncotarget - 9(1):812-823. doi: 10.18632/oncotarget.22549. ePub 2018 Jan 2.
Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer. Bartl T, Schwameis R, Stift A, Bachleitner-Hofmann T, Reinthaller A, Grimm C, Polterauer S.Int J Gynecol Cancer. 2018 Nov;28(9):1664-1671. doi:10.1097/IGC.0000000000001369.
A POLYMER LIGAND-BASED ELISA FOR ROBUST, HIGH-THROUGHPUT, QUANTITATIVE DETECTION OF P53 AGGREGATES.Maritschnegg E, Heinzl N, Wilson S, Deycmar S, Niebuhr M, Klameth L, Holzer B, Koziel K, Concin N, Zeillinger R. Anal Chem.; 2018 Nov 20; 90(22):13273-13279
UTERINE AND TUBAL LAVAGE FOR EARLIER CANCER DETECTION USING AN INNOVATIVE CATHETER: A FEASIBILITY AND SAFETY STUDY.. Maritschnegg E, Heitz F, Pecha N, Bouda J, Trillsch F, Grimm C, Vanderstichele A, Agreiter C, Harter P, Obermayr E, Vergote I, Zeillinger R, Speiser P. Int J Gynecol Cancer; 2018 Nov 28(9):1692-1698
CLINICAL SIGNIFICANCE OF ORGANIC ANION TRANSPORTING POLYPEPTIDE GENE EXPRESSION IN HIGH-GRADE SEROUS OVARIAN CANCER. Svoboda M, Mungenast F, Gleiss A, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Jäger W, Mechtcheriakova D, Cacsire-Tong D, Zeillinger R, Thalhamer T, Pils D. Front Pharmacol.; 2018 Aug 7 (9):842
CORRECTION: DIAGNOSTIC MARKERS FOR THE DETECTION OF OVARIAN CANCER IN BRCA1 MUTATION CARRIERS. Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF. PLoS One; 2018 Apr 17; 13(4):e0196142
IMMUNOBIOCHEMICAL PATHWAYS OF NEOPTERIN FORMATION AND TRYPTOPHAN BREAKDOWN VIA INDOLEAMINE 2,3-DIOXYGENASE CORRELATE WITH CIRCULATING TUMOR CELLS IN OVARIAN CANCER PATIENTS – A STUDY OF THE OVCAD CONSORTIUM. Gostner JM, Obermayr E, Braicu IE, Concin N, Mahner S, Vanderstichele A, Sehouli J, Vergote I, Fuchs D, Zeillinger R. Gynecol Oncol.; 2018 May; 149(2):371-380.
EFFICIENT LEUKOCYTE DEPLETION BY A NOVEL MICROFLUIDIC PLATFORM ENABLES THE MOLECULAR DETECTION AND CHARACTERIZATION OF CIRCULATING TUMOR CELLS. Obermayr E, Maritschnegg E, Agreiter C, Pecha N, Speiser P, Helmy-Bader S, Danzinger S, Krainer M, Singer C, Zeillinger R. Oncotarget; 2017 Nov 28; 9(1):812-823
Treatment of Cervicofacial Lymphaticovenous Malformation with Vascularized Lymph Node Transfer. Roka-Palkovits J, Steinbacher J, Tinhofer I, Pona I, Matzek WK, Staudenherz A, Rath T, Radtke C, Weninger W, Tzou CJ. Plast Reconstr Surg. 2018 Sep;142(3):425e-426e. doi: 10.1097/PRS.0000000000004628
Assessing the kidney function parameters glomerular filtration rate and effective renal plasma flow with dynamic FDG-PET/MRI in healthy subjects. Geist BK, Baltzer P, Fueger B, Hamboeck M, Nakuz T, Papp L, Rasul S, Sundar LKS, Hacker M, Staudenherz A. EJNMMI Res. 2018 May 9;8(1):37. doi: 10.1186/s13550-018-0389-1.
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Böhmig GA. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14.
Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18 F]FDG-PET imaging. Is it of value in asymptomatic patients?Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, Aszmann O, Hojreh A, Peyrl A, Amann G, Benkoe TM, Wadsak W, Kasprian G, Staudenherz A, Hacker M, Traub-Weidinger T. Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26733. Epub 2017 Aug 3.
Association of endogenous circulating sex steroids and condition-specific quality of life domains in postmenopausal women with pelvic floor disorders. Bodner-Adler B, Bodner K, Kimberger O, Halpern K, Koelbl H, Umek W. Arch Gynecol Obstet. 2018 Mar;297(3):725-730. doi: 10.1007/s00404-018-4650-7. Epub 2018 Jan 15
AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer - a retrospective multi-centre study. Seebacher V, Polterauer S, Reinthaller A, Koelbl H, Achleitner R, Berger A, Concin N. BMC Cancer. 2018 Apr 19;18(1):447. doi: 10.1186/s12885-018-4289-6.
»Serum proteomic pattern in female stress urinary incontinence. Koch M, Umek W, Hanzal E, Mohr T, Seyfert S, Koelbl H, Mitulović G.Electrophoresis. 2018 Apr;39(8):1071-1078. doi: 10.1002/elps.201700423. Epub 2018 Feb 6.
Association of uterine leiomyoma and overactive bladder syndrome. Koch M, Rauchenwald T, Kivaranovic D, Schwab S, Umek W, Koelbl H, Rauchenwald M, Helmy S. Int J Gynaecol Obstet. 2018 Sep;142(3):365-369. doi: 10.1002/ijgo.12545. Epub 2018 Jun 28.
Co-expressed genes enhance precision of receptor status identification in breast cancer patients. Kenn M, Cacsire Castillo-Tong D, Singer CF, Cibena M, Kölbl H, Schreiner W.Breast Cancer Res Treat. 2018 Nov;172(2):313-326. doi: 10.1007/s10549-018-4920-x. Epub 2018 Aug 16.
Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory.Reich O, Braune G, Eppel W, Fiedler T, Graf A, Hefler L, Joura E, Kölbl H, Marth C, Pokieser W, Regitnig P, Reinthaller A, Tamussino K, Widschwendter A, Zeimet A, Kohlberger P.Geburtshilfe Frauenheilkd. 2018 Dec;78(12):1232-1244. doi: 10.1055/a-0764-4875. Epub 2018 Dec 14.
»Risk and protective factors for obstetric anal sphincter injuries: A retrospective nationwide study.Marschalek ML, Worda C, Kuessel L, Koelbl H, Oberaigner W, Leitner H, Marschalek J, Husslein H.Birth. 2018 Dec;45(4):409-415. doi: 10.1111/birt.12346. Epub 2018 Mar 14
Kreuzinger, C., Geroldinger, A., Smeets, D., Braicu, E. I., Sehouli, J., Koller, J., Wolf, A., Darb-Esfahani, S., Joehrens, K., Vergote, I., Vanderstichele, A., Boeckx, B., Lambrechts, D., Gabra, H., Wisman, G. B. A., Trillsch, F., Heinze, G., Horvat, R., Polterauer, S., Berns, E., … Cacsire Castillo-Tong, D. (2017). A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(24), 7621–7632. https://doi.org/10.1158/1078-0432.CCR-17-1159
Comparison of a prototype reverse hybridization assay and MethyLight for detection of SFRP2 promotor methylation in fecal DNA.Kriegshäuser G, Enko D, Zitt M, Oberwalder M, Oberkanins C, Öfner D, Zeillinger R, Maximilian Müller H.. Int J Biol Markers. 2017 Oct 31;32(4):e467-e470. doi: 10.5301/ijbm.5000289. PubMed PMID: 28777432.
Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance. Klameth L, Rath B, Hochmaier M, Moser D, Redl M, Mungenast F, Gelles K, Ulsperger E, Zeillinger R, Hamilton G. Sci Rep. 2017 Jul 13;7(1):5337. doi: 10.1038/s41598-017-05562-z. PubMed PMID: 28706293; PubMed Central PMCID: PMC5509650.
»Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin? Sukhbaatar N, Bachmayr-Heyda A, Auer K, Aust S, Deycmar S, Horvat R, Pils D. Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001461. doi: 10.1101/mcs.a001461. Print 2017 Jul. PubMed PMID: 28679689; PubMed Central PMCID:PMC5495036.
»EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. Dis Markers. Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, Pecha N, Mandorfer M, Pils D, Brisson AR, Zeillinger R, Lim SK.. 2017;2017:9653194. doi: 10.1155/2017/9653194. Epub 2017 May 16. PubMed PMID: 28607529; PubMed Central PMCID: PMC5451862.
»PARP inhibition causes premature loss of cohesion in cancer cells. Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D.Oncotarget. 2017 Oct 16;8(61):103931-103951. doi: 10.18632/oncotarget.21879. eCollection 2017 Nov 28. PubMed PMID: 29262611; PubMed Central PMCID: PMC5732777.
»Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget. Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong,DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C,Zeillinger R, Brandt B. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017Dec 5. PubMed PMID: 29290959; PubMed Central PMCID: PMC5739744.
»EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. Dis Markers. Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, Pecha N, Mandorfer M, Pils D, Brisson AR, Zeillinger R, Lim SK.. 2017;2017:9653194. doi: 10.1155/2017/9653194. Epub 2017 May 16. PubMed PMID: 28607529; PubMed Central PMCID: PMC5451862.
Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, Zeillinger R, Thalhammer T. Oncol Lett. 2017 Jun;13(6):4047-4054. doi: 10.3892/ol.2017.5969. Epub 2017 Apr 3. PubMed PMID: 28588698; PubMed Central PMCID: PMC5452883.
Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Pavo N, Lukovic D, Zlabinger K, Zimba A, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Jan Ankersmit H, Giricz Z, Baranyai T, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M. Sci Rep. 2017 Mar 7;7:43958. doi: 10.1038/srep43958. PubMed PMID: 28266659; PubMed Central PMCID: PMC5339807.
T.Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N,Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E,Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE,Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN,Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi Cancer Res. 2017 Mar 15;77(6):1250-1260. doi:10.1158/0008-5472.CAN-16-2179. Review. PubMed PMID: 28254861.
Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary,with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Auer K, Bachmayr-Heyda A, Aust S, Grunt TW, Pils D. Cancer Lett. 2017 Mar 1;388:158-166. doi: 10.1016/j.canlet.2016.11.034. Epub 2016Dec 7. PubMed PMID: 27940126.
Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer.Bachmayr-Heyda A, Aust S, Auer K, Meier SM, Schmetterer KG, Dekan S, Gerner C, Pils D. Clin Cancer Res. 2017 Apr 15;23(8):2081-2092.doi: 10.1158/1078-0432.CCR-16-1647. Epub 2016 Oct 19. PubMed PMID: 27797973.
Immunogenicity, and safety of a nine-valent human papillomavirus vaccine in women aged 16-26 years: Final analyses of a randomised, double-blind trial
Huh W, Joura EA, Giuliano AR, IversenOE, Rosires Pereira de Andrade, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Alain Luxembourg A. Efficacy
Lancet 2017;390:2143-59
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analyses of five phase III clinical trials
Petersen LK, Restrepo J, Moreira ED, Iversen OE, Pitisuttithum P, Van Damme P, Joura EA, Olsson SE, Ferris D, Block S, Giuliano AR, Bosch X, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista O, Hyatt D, Maansson R, Moeller E, Qi H, Roberts C, Luxembourg A. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analyses of five phase III clinical trials.
Papillomavirus Res 2017;3:105-15
The Impact of Written Information and Counseling (WOMAN-PRO II Program) on Symptom Outcomes in Women with Vulvar Neoplasia: A Multicenter Randomized Controlled Phase II Study
Raphaelis S, Mayer H, Ott S, Mueller MD, Steiner E, Joura E, Senn B.
Gynecol Oncol 2017;146:114-22
Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine
Guevara A, Cabello R, Woelber L, Moreira ED, Joura E, Reich O, Shields C, Ellison M, Joshi A, Luxembourg
Vaccine 2017;35:5050-7
Safety profile of the 9-Valent HPV vaccine: A combined analysis of 7 Phase III clinical trials Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D,
Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A .
Pediatrics 2016; 138. pii: e20154387. ,IF: 5,8
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria Boiron L, Joura E, Largeron N, Prager B, Uhart M. BMC Infect Dis 2016;16:153. doi:10.1186/s12879-016-1483-5. , IF: 2, 17
Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines
Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Vaccine 2016;34:757-61. ,IF:3,624
Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients
Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Cacsire Castillo-Tong D, Wisman GB, Berns EM, Siddiqui N, Paul J, Brown R.
Clin Cancer Res. 2016 Sep 23. PMID: 27663594
Short-Term Efficacy of Trichloroacetic Acid in the Treatment of Cervical Intraepithelial Neoplasia
Geisler S, Speiser S, Speiser L, Heinze G, Rosenthal A, Speiser P. Obstet Gynecol. 2016 Feb;127(2):353-9.
Association of HER2 codon 655 polymorphism with ovarian cancer
Watrowski R, Castillo-Tong DC, Schuster E, Fischer MB, Speiser P, Zeillinger R. Tumour Biol. 2016 Jun;37(6):7239-44. doi: 10.1007/s13277-015-4609-2. PMID: 26666819
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote . Eur J Cancer. 2016 Jan;53:51-64. PMID: 26693899
Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype
Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R. Cell Adh Migr. 2016 Jul 3;10(4):360-7. PMID: 26919626
Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies
Kuessel L, Kasimir-Bauer S, Zeillinger R, Pateisky P, Ott J, Zeisler H, Birdir C. Hypertens Pregnancy. 2016 Aug; 35(3):323-9 PMID: 26930176
Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, VAN Nieuwenhuysen E, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI. Anticancer Res. 2016 Mar;36(3):1015-22. PMID: 26976992
Statistical controversies in clinical research: the importance of importance
Gleiss A, Zeillinger R, Braicu EI, Trillsch F, Vergote I, Schemper M.
Ann Oncol. 2016 Jul; 27(7):1185-9. PMID: 27052655
Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer"
[Eur J Cancer 53 (2016) 51-64]
Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Castillo-Tong DC, Lambrechts D, Vergote I. .Eur J Cancer. 2016 Jun; 60:226. PMID: 27106403
AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
Svoboda M, Meshcheryakova A, Heinze G, Jaritz M, Pils D, Castillo-Tong DC, Hager G, Thalhammer T, Jensen-Jarolim E, Birner P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Zimmermann P, Zeillinger R, Mechtcheriakova D. BMC Genomics. 2016 Aug 16; 17(1):643. PMID:
27527602
Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors
Watrowski R, Heinze G, Jäger C, Forster J, Zeillinger R.
Tumour Biol. 2016 Sep; 37(9):12079-12087. PMID: 27207344
Effect of Preoperative Warm-up Exercise Before Laparoscopic Gynecological Surgery: A Randomized Trial
Polterauer S, Husslein H, Kranawetter M, Schwameis R, Reinthaller A, Heinze G, Grimm C. J Surg Educ. 2016 May-Jun;73(3):429-32. PMID: 26778744
Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015)
Tempfer C, Horn LC, Ackermann S, Beckmann MW, Dittrich R, Einenkel J, Günthert A, Haase H, Kratzsch J, Kreissl MC, Polterauer S, Ebert AD, Schneider KT, Strauss HG, Thiel F. Geburtshilfe Frauenheilkd. 2016 Feb;76(2):134-144. PMID: 26941444
»Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature
Mailath-Pokorny M, Schwameis R, Grimm C, Reinthaller A, Polterauer S. BMC Pregnancy Childbirth. 2016 Apr 7;16:74. PMID: 27055819
Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study
Pinker K, Andrzejewski P, Baltzer P, Polanec SH, Sturdza A, Georg D, Helbich TH, Karanikas G, Grimm C, Polterauer S, Poetter R, Wadsak W, Mitterhauser M, Georg P. PLoS One. 2016 May 11;11(5). PMID: 27167829
Risk Factors for De Novo Malignancies in Women After Kidney Transplantation: A Multicenter Transversal Study
Helmy S, Marschalek J, Bader Y, Koch M, Schmidt A, Kanzler M, Gyoeri G, Polterauer S, Reinthaller A, Grimm C. Int J Gynecol Cancer. 2016 Jun;26(5):967-70. PMID: 27206219
The prognostic role of metformin in patients with endometrial cancer: a retrospective study Seebacher V, Bergmeister B, Grimm C, Koelbl H, Reinthaller A, Polterauer S. Eur J Obstet Gynecol Reprod Biol. 2016 Aug;203:291-6. PMID: 27423029
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid
Zeitlinger M, Schwameis R, Burian A, Burian B, Matzneller P, Müller M, Wicha WW, Strickmann DB, Prince W. . J Antimicrob Chemother. 2016
Apr;71(4):1022-6. PMID:26747098
Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo- Controlled Trial
Schwameis R, Pils S, Weber M, Hagmann M, Zeitlinger M, Sauermann R.
Pharmacology. 2016; 98(1-2):93-8. PMID: 27165542
Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma Schwameis R, Grimm C, Brodowicz T, Petru E, Hefler-Frischmuth K, Staudigl C, Reinthaller A, Heinze G, Polterauer S, Polterauer M. Sci Rep. 2016 Sep 20;6: 33757. PMID: 27646551
Training on an inexpensive tablet-based device is equally effective as on a standard laparoscopic box trainer: A randomized controlled trial
Montanari E, Schwameis R, Louridas M, Göbl C, Kuessel L, Polterauer S, Husslein H. Medicine (Baltimore). 2016 Sep; 95(39):e4826.PMID:27684813
Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV
Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S, du Bois A. Gynecol Oncol. 2016 Feb;140(2):215-20. PMID: 26691222
Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer Prader S, Harter P, Grimm C, Traut A, Waltering KU, Alesina PF, Heikaus S, Ataseven B, Heitz F, Schneider S, du Bois A. Gynecol Oncol. 2016 May; 141(2):271-5 PMID: 26972337
Risk Factors for De Novo Malignancies in Women After Kidney Transplantation: A Multicenter Transversal Study
Helmy S, Marschalek J, Bader Y, Koch M, Schmidt A, Kanzler M, Gyoeri G, Polterauer S, Reinthaller A, Grimm C. Int J Gynecol Cancer. 2016 Jun; 26(5):967-70. PMID: 27206219
The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
Ataseven B, Harter P, Grimm C, Heitz F, Heikaus S, Traut A, Kahl A, Kurzeder C, Prader S, du Bois A. Gynecol Oncol. 2016 Aug;142(2):243-7. PMID: 27208538
Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer
Ataseven B, Grimm C, Harter P, Heikaus S, Heitz F, Traut A, Prader S, Kahl A, Schneider S, Kurzeder C, du Bois A. Ann Surg Oncol. 2016 Jul 12. [Epub ahead of print] PMID: 27406097
Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer
Ataseven B, du Bois A, Harter P, Prader S, Grimm C, Kurzeder C, Schneider S, Heikaus S, Kahl A, Traut A, Heitz F. Int J Gynecol Cancer. 2016 Nov; 26(9):1594-1600. PMID: 27654263
Role of the immune system in the peritoneal tumor spread of high grade serous
Auer K, Bachmayr-Heyda A, Sukhbaatar N, Aust S, Schmetterer KG, Meier SM, Gerner C, Grimm C, Horvat R, Pils D. ovarian cancer. Oncotarget. 2016 Aug 3:61336-61354.PMID: 27665539
Small RNAs and the competing endogenous RNA network in high grade serous ovarian Bachmayr-Heyda A, Auer K, Sukhbaatar N, Aust S, Deycmar S, Reiner AT, Polterauer S, Dekan S, Pils D. cancer tumor spread. Oncotarget. 2016 Jun 28;7(26):39640-39653.PMID: 27172797
Antiangiogenic therapies in ovarian cancer
Reinthaller A.. 2016;9(3):139-143. Review.
PMID:27752291
Topotecan plus carboplatin versus standard therapy with paclitaxel
plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
Canzler U, Mahner S, Meier W.
Ann Oncol. 2016 Oct 26. pii: mdw418. [Epub ahead of print] PMID:27789470
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study
Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W,
Angleitner-Boubenizek L, Brandt B, Chekerov R.
Br J Cancer. 2014 Sep 16. doi: 10.1038/bjc.2014.443.
[Epub ahead of print] PubMed PMID: 25225907.
A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial
Grimm C, Polterauer S, Helmy S, Cibula D, Zikan M, Reinthaller A, Tempfer C.
BMC Cancer. 2014 Aug 30;14:635. doi: 10.1186/1471-2407-14-635.
PubMed PMID: 25175029; PubMed Central PMCID: PMC4156659.
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall
M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M,
Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.
J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669.
Epub 2013 Dec 23. PubMed PMID: 24366937.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E,
Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I,
Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011.
Epub 2013 Oct 28. PubMed PMID: 24176298.
The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer
Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L, PolterauerS.
Eur J Obstet Gynecol Reprod Biol. 2013 Nov;171(1):101-6. doi:10.1016/j.ejogrb.2013.07.044. Epub 2013 Aug 11.
PubMed PMID: 24011381.
Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G,
Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S.
Br J Cancer. 2013 Aug 6;109(3):610-4. doi: 10.1038/bjc.2013.323.
Epub 2013 Jul 16. PubMed PMID: 23921280; PubMed Central PMCID: PMC3738124.
Association of myeloperoxidase with ovarian cancer
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A,
Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.
Tumour Biol. 2014 Jan;35(1):141-8. doi:10.1007/s13277-013-1017-3.
Epub 2013 Jul 27. PubMed PMID: 23893381; PubMed Central PMCID: PMC4039294.
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation
Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA,
Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.
J Natl Cancer Inst. 2013 Aug7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763. PubMed PMID: 23781004.
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial
Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R,
Taucher S, Wagener A, Marth C, Concin N.
Br J Cancer. 2013 Jul 9;109(1):215-8. doi: 10.1038/bjc.2013.282.
Epub 2013 Jun 13. PubMed PMID: 23764750; PubMed Central PMCID: PMC3708572.
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.
Gynecol Oncol. 2013 Aug;130(2):289-94. doi: 10.1016/j.ygyno.2013.05.013.
Epub 2013 May 18. PubMed PMID: 23694718.
Impact of conization type on the resected cone volume: results of a
retrospective multi-center study
Grimm C, Brammen L, Sliutz G, Weigert M, Sevelda P, Pils S, Reinthaller A,
Polterauer S.
Arch Gynecol Obstet. 2013 Nov;288(5):1081-6.
doi: 10.1007/s00404-013-2873-1. Epub 2013 May 7. PubMed PMID: 23649464.
The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser
P, Reinthaller A, Polterauer S.
BMC Cancer. 2013 Mar 14;13:115. doi: 10.1186/1471-2407-13-115.
PubMed PMID: 23497172; PubMed Central PMCID: PMC3605348.
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer
Aust S, Pils S, Polterauer S, Horvat R, Cacsire Castillo-Tong D, Pils D,
Dudek G, Schmid B, Speiser P, Reinthaller A, Grimm C.
Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):518-24.
doi: 10.1097/PAI.0b013e318284a053. PubMed PMID: 23455184.
HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium
Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S,
Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J.
Onco Targets Ther. 2014 Sep 11;7:1563-9. doi: 10.2147/OTT.S65373. eCollection 2014. PubMed PMID: 25246800; PubMed Central PMCID: PMC4166345.
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F,
Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N,
Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001.
Epub 2014 Jun 2. PubMed PMID: 24889916.
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium
Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S,
Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils
D.Mol Cancer. 2014 Mar 21;13:67. doi: 10.1186/1476-4598-13-67.
PubMed PMID: 24655477; PubMed Central PMCID: PMC3998046.
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma
Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C,
Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H,
Altevogt P.
Oncotarget 2014 Jan 30;5(2):462-72. PubMed PMID: 24497324;
PubMed Central PMCID: PMC3964221.
Association of TAP gene polymorphismsand risk of cervical intraepithelial neoplasia
Natter C, Polterauer S, Rahhal-Schupp J, Cacsire Castillo-Tong D, Pils S,
Speiser P, Zeillinger R, Heinze G, Grimm C.
Dis Markers. 2013;35(2):79-84. doi: 10.1155/2013/368732.
Epub 2013 Jul 28. PubMed PMID: 24288424; PubMed Central PMCID: PMC3774964
Known players, new interplay in atherogenesis: Chronic shear stress and carbamylated-LDL induce and modulateexpression of atherogenic LR11 in human coronary artery endothelium
Bajari TM, Winnicki W, Gensberger ET, Scharrer SI, Regele H, Aumayr K, Kopecky C, Gmeiner BM, Hermann M, Zeillinger R, Sengölge G.
Thromb Haemost. 2014 Feb;111(2):323-32. doi: 10.1160/TH12-12-0924.
Epub 2013 Nov 28. PubMed PMID: 24284991.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E,
Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I,
Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011.
Epub 2013 Oct 28. PubMed PMID: 24176298.
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium
Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli
J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.
BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422.
PubMed PMID: 24044611; PubMed Central PMCID: PMC3848589.
eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women
Groten T, Schleussner E, Lehmann T, Reister F, Holzer B, Danso KA, Zeillinger R.
Arch Gynecol Obstet. 2014 Mar;289(3):581-93. doi: 10.1007/s00404-013-2991-9.
Epub 2013 Sep 8. PubMed PMID: 24013430.
Association of myeloperoxidase with ovarian cancer
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A,
Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF
Tumour Biol. 2014 Jan;35(1):141-8. doi:10.1007/s13277-013-1017-3.
Epub 2013 Jul 27. PubMed PMID: 23893381; PubMed Central PMCID: PMC4039294.
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp
T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet
AG, Vergote I.
Gynecol Oncol. 2013 Oct;131(1):15-20. doi: 10.1016/j.ygyno.2013.07.086.
Epub 2013 Jul 20. PubMed PMID: 23877013.
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van
Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R,
Vergote I, Mahner S, Sehouli J.
J Ovarian Res. 2013 Jun 28;6(1):42. doi: 10.1186/1757-2215-6-42.
PubMed PMID: 23809664; PubMed Central PMCID: PMC3707788.
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium
Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E,
Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser
P, Zeillinger R.
BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.
PubMed PMID: 23551967; PubMed Central PMCID: PMC3639192.
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer
Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M,
Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC.
Int J Gynecol Pathol. 2013 May;32(3):269-76. doi: 10.1097/PGP.0b013e31826a63f8. PubMed PMID:23518910.
The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors
Secky L, Svoboda M, Klameth L, Bajna E, Hamilton G, Zeillinger R, Jäger W,
Thalhammer T.
J Drug Deliv.2013;2013:957605. doi: 10.1155/2013/957605.
Epub 2013 Feb 13. PubMed PMID: 23476785; PubMed Central PMCID: PMC3586502.
Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells
Vaňhara P, Horak P, Pils D, Anees M, Petz M, Gregor W, Zeillinger R, Krainer M.
Int J Oncol. 2013 Apr;42(4):1383-9. doi:10.3892/ijo.2013.1824.
Epub 2013 Feb 12. PubMed PMID: 23404293.
Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S,
Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 2013 Feb;23(2):268-75. doi: 10.1097/IGC.0b013e31827de6b9. PubMed PMID: 23358178.
Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens
Buxhofer-Ausch V, Ausch C, Zeillinger R, Oberkanins C, Dandachi N,
Reiner-Concin A, Kriegshäuser G.
Dis Markers. 2013;34(3):171-7. doi:10.3233/DMA-120960.
PubMed PMID: 23324583; PubMed Central PMCID: PMC3810114.
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study
Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H,
Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J.
Gynecol Oncol. 2013 Feb;128(2):245-51. doi: 10.1016/j.ygyno.2012.11.023.
Epub 2012 Nov 21. PubMed PMID: 23178313
Posttraumatic Stress Disorder After High-Dose-Rate Brachytherapy for Cervical Cancer With 2 Fractions in 1 Application Under Spinal/Epidural Anesthesia: Incidence and Risk Ractors.Kirchheiner K, Czajka-Pepl A, Ponocny-Seliger E, Scharbert G, Wetzel L, Nout RA, Sturdza A, Dimopoulos JC, Dörr W, Pötter R.
Int J Radiat Oncol Biol Phys. 2014 Apr 7.
Manifestation Pattern of Early-Late Vaginal Morbidity After Definitive Radiation (Chemo)Therapy and Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: An Analysis From the EMBRACE Study.
Kirchheiner K, Nout RA, Tanderup K, Lindegaard JC, Westerveld H, Haie-Meder C, Petrič P, Mahantshetty U, Dörr W, Pötter R. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):88-95.
Universal vaccination with the quadrivalent HPV vaccine in Austria: Impact on virus circulation, public health and cost-effectiveness analysis.
Bresse X, Goergen C, Prager B, Joura E.
Expert Rev Pharmacoecon Outcomes Res. 2014 Jan 22.
TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in vivo. Horak P, Tomasich E, Vanhara P, Kratochvílová K, Anees M, Marhold M, Lemberger CE, Gerschpacher M, Horvat R, Sibilia M, Pils D, Krainer M. Sci Rep. 2014 Jan 17;4:3739.
Association of myeloperoxidase with ovarian cancer.Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF. Tumour Biol. 2014 Jan;35(1):141-8.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110.
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P. Oncotarget. 2014 Jan 12.
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study.
Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.
J Clin Oncol. 2013 Dec 23.
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
Aust S, Pils S, Polterauer S, Horvat R, Cacsire Castillo-Tong D, Pils D, Dudek G, Schmid B, Speiser P, Reinthaller A, Grimm C.
Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):518-24.
Increase in ezrin expression from benign to malignant breast tumours.
Gschwantler-Kaulich D, Natter C, Steurer S, Walter I, Thomas A, Salama M, Singer CF.
Cell Oncol (Dordr). 2013 Dec;36(6):485-91.
The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer.
Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L, Polterauer S. Eur J Obstet Gynecol Reprod Biol. 2013 Nov;171(1):101-6.
Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM.
Kirisits C, Rivard MJ, Baltas D, Ballester F, De Brabandere M, van der Laarse R, Niatsetski Y, Papagiannis P, Hellebust TP, Perez-Calatayud J, Tanderup K, Venselaar JL, Siebert FA.
Radiother Oncol. 2013 Nov 30.
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva.
de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, Joura EA, Maldonado P, Laco J, Bravo IG, Vidal A, Guimerà N, Cross P, Wain GV, Petry KU, Mariani L, Bergeron C, Mandys V, Sica AR, Félix A, Usubutun A, Seoud M, Hernández-Suárez G, Nowakowski AM, Wilson G, Dalstein V, Hampl M, Kasamatsu ES, Lombardi LE, Tinoco L, Alvarado-Cabrero I, Perrotta M, Bhatla N, Agorastos T, Lynch CF, Goodman MT, Shin HR, Viarheichyk H, Jach R, Cruz MO, Velasco J, Molina C, Bornstein J, Ferrera A, Domingo EJ, Chou CY, Banjo AF, Castellsagué X, Pawlita M, Lloveras B, Quint WG, Muñoz N, Bosch FX; HPV VVAP study group.
Eur J Cancer. 2013 Nov;49(16):3450-61.
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study.
Rössler L, Reich O, Horvat R, de Souza SC, Holl K, Joura EA.
Wien Klin Wochenschr. 2013 Oct;125(19-20):591-9.
High-risk clinical target volume delineation in CT-guided cervical cancer brachytherapy: impact of information from FIGO stage with or without systematic inclusion of 3D documentation of clinical gynecological examination.
Hegazy N, Pötter R, Kirisits C, Berger D, Federico M, Sturdza A, Nesvacil N.
Acta Oncol. 2013 Oct;52(7):1345-52.
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.
Gynecol Oncol. 2013 Oct;131(1):15-20.
Association of TAP Gene Polymorphisms and Risk of Cervical Intraepithelial Neoplasia. Natter C, Polterauer S, Rahhal-Schupp J, Cacsire Castillo-Tong D, Pils S, Speiser P, Zeillinger R, Heinze G, Grimm C.
Dis Markers. 2013;35(2):79-84.
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.
BMC Cancer. 2013 Sep 17;13:422.
» L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.
J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50.
Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer.
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S.
Br J Cancer. 2013 Aug 6;109(3):610-4.
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.
Gynecol Oncol. 2013 Aug;130(2):289-94.
Single line source with and without vaginal loading and the impact on target coverage and organ at risk doses for cervix cancer Stages IB, II, and IIIB: treatment planning simulation in patients treated with MRI-guided adaptive brachytherapy in a multicentre study (EMBRACE).
Nkiwane KS, Pötter R, Tanderup K, Federico M, Lindegaard JC, Kirisits C.
Brachytherapy. 2013 Jul-Aug;12(4):317-23.
Association of myeloperoxidase with ovarian cancer.
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.
Tumor Biol. 2013 Jul 27.
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial.
Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R, Taucher S, Wagener A, Marth C, Concin N.
Br J Cancer. 2013 Jul 9;109(1):215-8.
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.
Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R, Vergote I, Mahner S, Sehouli J.
J Ovarian Res. 2013 Jun 28;6(1):42.
IL-24 sensitizes tumor cells to TLR3-mediated apoptosis.
Weiss R, Sachet M, Zinngrebe J, Aschacher T, Krainer M, Hegedus B, Walczak H, Bergmann M.
Cell Death Differ. 2013 Jun;20(6):823-33.
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer.
Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M, Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC.
Int J Gynecol Pathol. 2013 May;32(3):269-76.
Impact of conization type on the resected cone volume: results of a retrospective multi-center study.
Grimm C, Brammen L, Sliutz G, Weigert M, Sevelda P, Pils S, Reinthaller A, Polterauer S. Arch Gynecol Obstet. 2013 May 7.
A multicentre comparison of the dosimetric impact of inter- and intra-fractional anatomical variations in fractionated cervix cancer brachytherapy.
Nesvacil N, Tanderup K, Hellebust TP, De Leeuw A, Lang S, Mohamed S, Jamema SV, Anderson C, Pötter R, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):20-5.
Uncertainties in image guided adaptive cervix cancer brachytherapy: impact on planning and prescription.
Tanderup K, Nesvacil N, Pötter R, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):1-5.
Uncertainty analysis for 3D image-based cervix cancer brachytherapy by repetitive MR imaging: assessment of DVH-variations between two HDR fractions within one applicator insertion and their clinical relevance.
Lang S, Nesvacil N, Kirisits C, Georg P, Dimopoulos JC, Federico M, Pötter R.
Radiother Oncol. 2013 Apr;107(1):26-31.
Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytherapy.
Westerveld H, Pötter R, Berger D, Dankulchai P, Dörr W, Sora MC, Pötter-Lang S, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):99-105.
The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.
Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser P, Reinthaller A, Polterauer S.
BMC Cancer. 2013 Mar 14;13:115.
Methylation status of TUSC3 is a prognostic factor in ovarian cancer.
Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M.
Cancer. 2013 Mar 1;119(5):946-54.
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women.
Clark LR, Myers ER, Huh W, Joura EA, Paavonen J, Perez G, James MK, Sings HL, Haupt RM, Saah AJ, Garner EI. Clinical trial experience with prophylactic human papillomavirus 6/11/16/black women.
J Adolesc Health. 2013 Mar;52(3):322-9.
» Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 2013 Feb;23(2):268-75.
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K; HERACLES/SCALE Study Group.
Int J Cancer. 2013 Feb 15;132(4):854-67.
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.
Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R
Gynecol Oncol. 2013 Jan;128(1):15-21.
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: Results from the OVCAD study.
Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J.
Gynecol Oncol. 128:245-251, 2013.
Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.
Buxhofer-Ausch V, Ausch C, Zeillinger R, Oberkanins C, Dandachi N, Reiner-Concin A, Kriegshäuser G.
Dis Markers. 34(3):171-7, 2013.
Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 23(2):268-275, 2013.
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer-a study by the OVCAD consortium.
Melmer A, Fineder L, Lamina C, Kollerits B, Dieplinger B, Braicu I, Sehouli J, Cadron I, Vergote I, Mahner S, Zeimet AG, Castillo-Tong DC, Ebenbichler CF, Zeillinger R, Dieplinger H.
Gynecol Oncol. 128:38-43, 2013.
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.
BMC Cancer. 13:178, 2013.
Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.
Vaňhara P, Horak P, Pils D, Anees M, Petz M, Gregor W, Zeillinger R, Krainer M. Int J Oncol. 42(4):1383-9, 2013.
Kreuzinger, C., Geroldinger, A., Smeets, D., Braicu, E. I., Sehouli, J., Koller, J., Wolf, A., Darb-Esfahani, S., Joehrens, K., Vergote, I., Vanderstichele, A., Boeckx, B., Lambrechts, D., Gabra, H., Wisman, G. B. A., Trillsch, F., Heinze, G., Horvat, R., Polterauer, S., Berns, E., … Cacsire Castillo-Tong, D. (2017). A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(24), 7621–7632. https://doi.org/10.1158/1078-0432.CCR-17-1159
Comparison of a prototype reverse hybridization assay and MethyLight for detection of SFRP2 promotor methylation in fecal DNA.Kriegshäuser G, Enko D, Zitt M, Oberwalder M, Oberkanins C, Öfner D, Zeillinger R, Maximilian Müller H.. Int J Biol Markers. 2017 Oct 31;32(4):e467-e470. doi: 10.5301/ijbm.5000289. PubMed PMID: 28777432.
Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance. Klameth L, Rath B, Hochmaier M, Moser D, Redl M, Mungenast F, Gelles K, Ulsperger E, Zeillinger R, Hamilton G. Sci Rep. 2017 Jul 13;7(1):5337. doi: 10.1038/s41598-017-05562-z. PubMed PMID: 28706293; PubMed Central PMCID: PMC5509650.
»Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin? Sukhbaatar N, Bachmayr-Heyda A, Auer K, Aust S, Deycmar S, Horvat R, Pils D. Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001461. doi: 10.1101/mcs.a001461. Print 2017 Jul. PubMed PMID: 28679689; PubMed Central PMCID:PMC5495036.
»EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. Dis Markers. Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, Pecha N, Mandorfer M, Pils D, Brisson AR, Zeillinger R, Lim SK.. 2017;2017:9653194. doi: 10.1155/2017/9653194. Epub 2017 May 16. PubMed PMID: 28607529; PubMed Central PMCID: PMC5451862.
»PARP inhibition causes premature loss of cohesion in cancer cells. Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D.Oncotarget. 2017 Oct 16;8(61):103931-103951. doi: 10.18632/oncotarget.21879. eCollection 2017 Nov 28. PubMed PMID: 29262611; PubMed Central PMCID: PMC5732777.
»Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget. Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong,DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C,Zeillinger R, Brandt B. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017Dec 5. PubMed PMID: 29290959; PubMed Central PMCID: PMC5739744.
»EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. Dis Markers. Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, Pecha N, Mandorfer M, Pils D, Brisson AR, Zeillinger R, Lim SK.. 2017;2017:9653194. doi: 10.1155/2017/9653194. Epub 2017 May 16. PubMed PMID: 28607529; PubMed Central PMCID: PMC5451862.
Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, Zeillinger R, Thalhammer T. Oncol Lett. 2017 Jun;13(6):4047-4054. doi: 10.3892/ol.2017.5969. Epub 2017 Apr 3. PubMed PMID: 28588698; PubMed Central PMCID: PMC5452883.
Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Pavo N, Lukovic D, Zlabinger K, Zimba A, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Jan Ankersmit H, Giricz Z, Baranyai T, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M. Sci Rep. 2017 Mar 7;7:43958. doi: 10.1038/srep43958. PubMed PMID: 28266659; PubMed Central PMCID: PMC5339807.
T.Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N,Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E,Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE,Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN,Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi Cancer Res. 2017 Mar 15;77(6):1250-1260. doi:10.1158/0008-5472.CAN-16-2179. Review. PubMed PMID: 28254861.
Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary,with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Auer K, Bachmayr-Heyda A, Aust S, Grunt TW, Pils D. Cancer Lett. 2017 Mar 1;388:158-166. doi: 10.1016/j.canlet.2016.11.034. Epub 2016Dec 7. PubMed PMID: 27940126.
Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer.Bachmayr-Heyda A, Aust S, Auer K, Meier SM, Schmetterer KG, Dekan S, Gerner C, Pils D. Clin Cancer Res. 2017 Apr 15;23(8):2081-2092.doi: 10.1158/1078-0432.CCR-16-1647. Epub 2016 Oct 19. PubMed PMID: 27797973.
Immunogenicity, and safety of a nine-valent human papillomavirus vaccine in women aged 16-26 years: Final analyses of a randomised, double-blind trial
Huh W, Joura EA, Giuliano AR, IversenOE, Rosires Pereira de Andrade, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Alain Luxembourg A. Efficacy
Lancet 2017;390:2143-59
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analyses of five phase III clinical trials
Petersen LK, Restrepo J, Moreira ED, Iversen OE, Pitisuttithum P, Van Damme P, Joura EA, Olsson SE, Ferris D, Block S, Giuliano AR, Bosch X, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista O, Hyatt D, Maansson R, Moeller E, Qi H, Roberts C, Luxembourg A. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analyses of five phase III clinical trials.
Papillomavirus Res 2017;3:105-15
The Impact of Written Information and Counseling (WOMAN-PRO II Program) on Symptom Outcomes in Women with Vulvar Neoplasia: A Multicenter Randomized Controlled Phase II Study
Raphaelis S, Mayer H, Ott S, Mueller MD, Steiner E, Joura E, Senn B.
Gynecol Oncol 2017;146:114-22
Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine
Guevara A, Cabello R, Woelber L, Moreira ED, Joura E, Reich O, Shields C, Ellison M, Joshi A, Luxembourg
Vaccine 2017;35:5050-7
Safety profile of the 9-Valent HPV vaccine: A combined analysis of 7 Phase III clinical trials Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D,
Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A .
Pediatrics 2016; 138. pii: e20154387. ,IF: 5,8
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria Boiron L, Joura E, Largeron N, Prager B, Uhart M. BMC Infect Dis 2016;16:153. doi:10.1186/s12879-016-1483-5. , IF: 2, 17
Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines
Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Vaccine 2016;34:757-61. ,IF:3,624
Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients
Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Cacsire Castillo-Tong D, Wisman GB, Berns EM, Siddiqui N, Paul J, Brown R.
Clin Cancer Res. 2016 Sep 23. PMID: 27663594
Short-Term Efficacy of Trichloroacetic Acid in the Treatment of Cervical Intraepithelial Neoplasia
Geisler S, Speiser S, Speiser L, Heinze G, Rosenthal A, Speiser P. Obstet Gynecol. 2016 Feb;127(2):353-9.
Association of HER2 codon 655 polymorphism with ovarian cancer
Watrowski R, Castillo-Tong DC, Schuster E, Fischer MB, Speiser P, Zeillinger R. Tumour Biol. 2016 Jun;37(6):7239-44. doi: 10.1007/s13277-015-4609-2. PMID: 26666819
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote . Eur J Cancer. 2016 Jan;53:51-64. PMID: 26693899
Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype
Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R. Cell Adh Migr. 2016 Jul 3;10(4):360-7. PMID: 26919626
Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies
Kuessel L, Kasimir-Bauer S, Zeillinger R, Pateisky P, Ott J, Zeisler H, Birdir C. Hypertens Pregnancy. 2016 Aug; 35(3):323-9 PMID: 26930176
Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, VAN Nieuwenhuysen E, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI. Anticancer Res. 2016 Mar;36(3):1015-22. PMID: 26976992
Statistical controversies in clinical research: the importance of importance
Gleiss A, Zeillinger R, Braicu EI, Trillsch F, Vergote I, Schemper M.
Ann Oncol. 2016 Jul; 27(7):1185-9. PMID: 27052655
Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer"
[Eur J Cancer 53 (2016) 51-64]
Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Castillo-Tong DC, Lambrechts D, Vergote I. .Eur J Cancer. 2016 Jun; 60:226. PMID: 27106403
AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
Svoboda M, Meshcheryakova A, Heinze G, Jaritz M, Pils D, Castillo-Tong DC, Hager G, Thalhammer T, Jensen-Jarolim E, Birner P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Zimmermann P, Zeillinger R, Mechtcheriakova D. BMC Genomics. 2016 Aug 16; 17(1):643. PMID:
27527602
Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors
Watrowski R, Heinze G, Jäger C, Forster J, Zeillinger R.
Tumour Biol. 2016 Sep; 37(9):12079-12087. PMID: 27207344
Effect of Preoperative Warm-up Exercise Before Laparoscopic Gynecological Surgery: A Randomized Trial
Polterauer S, Husslein H, Kranawetter M, Schwameis R, Reinthaller A, Heinze G, Grimm C. J Surg Educ. 2016 May-Jun;73(3):429-32. PMID: 26778744
Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015)
Tempfer C, Horn LC, Ackermann S, Beckmann MW, Dittrich R, Einenkel J, Günthert A, Haase H, Kratzsch J, Kreissl MC, Polterauer S, Ebert AD, Schneider KT, Strauss HG, Thiel F. Geburtshilfe Frauenheilkd. 2016 Feb;76(2):134-144. PMID: 26941444
»Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature
Mailath-Pokorny M, Schwameis R, Grimm C, Reinthaller A, Polterauer S. BMC Pregnancy Childbirth. 2016 Apr 7;16:74. PMID: 27055819
Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study
Pinker K, Andrzejewski P, Baltzer P, Polanec SH, Sturdza A, Georg D, Helbich TH, Karanikas G, Grimm C, Polterauer S, Poetter R, Wadsak W, Mitterhauser M, Georg P. PLoS One. 2016 May 11;11(5). PMID: 27167829
Risk Factors for De Novo Malignancies in Women After Kidney Transplantation: A Multicenter Transversal Study
Helmy S, Marschalek J, Bader Y, Koch M, Schmidt A, Kanzler M, Gyoeri G, Polterauer S, Reinthaller A, Grimm C. Int J Gynecol Cancer. 2016 Jun;26(5):967-70. PMID: 27206219
The prognostic role of metformin in patients with endometrial cancer: a retrospective study Seebacher V, Bergmeister B, Grimm C, Koelbl H, Reinthaller A, Polterauer S. Eur J Obstet Gynecol Reprod Biol. 2016 Aug;203:291-6. PMID: 27423029
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid
Zeitlinger M, Schwameis R, Burian A, Burian B, Matzneller P, Müller M, Wicha WW, Strickmann DB, Prince W. . J Antimicrob Chemother. 2016
Apr;71(4):1022-6. PMID:26747098
Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo- Controlled Trial
Schwameis R, Pils S, Weber M, Hagmann M, Zeitlinger M, Sauermann R.
Pharmacology. 2016; 98(1-2):93-8. PMID: 27165542
Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma Schwameis R, Grimm C, Brodowicz T, Petru E, Hefler-Frischmuth K, Staudigl C, Reinthaller A, Heinze G, Polterauer S, Polterauer M. Sci Rep. 2016 Sep 20;6: 33757. PMID: 27646551
Training on an inexpensive tablet-based device is equally effective as on a standard laparoscopic box trainer: A randomized controlled trial
Montanari E, Schwameis R, Louridas M, Göbl C, Kuessel L, Polterauer S, Husslein H. Medicine (Baltimore). 2016 Sep; 95(39):e4826.PMID:27684813
Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV
Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S, du Bois A. Gynecol Oncol. 2016 Feb;140(2):215-20. PMID: 26691222
Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer Prader S, Harter P, Grimm C, Traut A, Waltering KU, Alesina PF, Heikaus S, Ataseven B, Heitz F, Schneider S, du Bois A. Gynecol Oncol. 2016 May; 141(2):271-5 PMID: 26972337
Risk Factors for De Novo Malignancies in Women After Kidney Transplantation: A Multicenter Transversal Study
Helmy S, Marschalek J, Bader Y, Koch M, Schmidt A, Kanzler M, Gyoeri G, Polterauer S, Reinthaller A, Grimm C. Int J Gynecol Cancer. 2016 Jun; 26(5):967-70. PMID: 27206219
The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
Ataseven B, Harter P, Grimm C, Heitz F, Heikaus S, Traut A, Kahl A, Kurzeder C, Prader S, du Bois A. Gynecol Oncol. 2016 Aug;142(2):243-7. PMID: 27208538
Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer
Ataseven B, Grimm C, Harter P, Heikaus S, Heitz F, Traut A, Prader S, Kahl A, Schneider S, Kurzeder C, du Bois A. Ann Surg Oncol. 2016 Jul 12. [Epub ahead of print] PMID: 27406097
Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer
Ataseven B, du Bois A, Harter P, Prader S, Grimm C, Kurzeder C, Schneider S, Heikaus S, Kahl A, Traut A, Heitz F. Int J Gynecol Cancer. 2016 Nov; 26(9):1594-1600. PMID: 27654263
Role of the immune system in the peritoneal tumor spread of high grade serous
Auer K, Bachmayr-Heyda A, Sukhbaatar N, Aust S, Schmetterer KG, Meier SM, Gerner C, Grimm C, Horvat R, Pils D. ovarian cancer. Oncotarget. 2016 Aug 3:61336-61354.PMID: 27665539
Small RNAs and the competing endogenous RNA network in high grade serous ovarian Bachmayr-Heyda A, Auer K, Sukhbaatar N, Aust S, Deycmar S, Reiner AT, Polterauer S, Dekan S, Pils D. cancer tumor spread. Oncotarget. 2016 Jun 28;7(26):39640-39653.PMID: 27172797
Antiangiogenic therapies in ovarian cancer
Reinthaller A.. 2016;9(3):139-143. Review.
PMID:27752291
Topotecan plus carboplatin versus standard therapy with paclitaxel
plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
Canzler U, Mahner S, Meier W.
Ann Oncol. 2016 Oct 26. pii: mdw418. [Epub ahead of print] PMID:27789470
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study
Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W,
Angleitner-Boubenizek L, Brandt B, Chekerov R.
Br J Cancer. 2014 Sep 16. doi: 10.1038/bjc.2014.443.
[Epub ahead of print] PubMed PMID: 25225907.
A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial
Grimm C, Polterauer S, Helmy S, Cibula D, Zikan M, Reinthaller A, Tempfer C.
BMC Cancer. 2014 Aug 30;14:635. doi: 10.1186/1471-2407-14-635.
PubMed PMID: 25175029; PubMed Central PMCID: PMC4156659.
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall
M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M,
Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.
J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669.
Epub 2013 Dec 23. PubMed PMID: 24366937.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E,
Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I,
Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011.
Epub 2013 Oct 28. PubMed PMID: 24176298.
The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer
Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L, PolterauerS.
Eur J Obstet Gynecol Reprod Biol. 2013 Nov;171(1):101-6. doi:10.1016/j.ejogrb.2013.07.044. Epub 2013 Aug 11.
PubMed PMID: 24011381.
Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G,
Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S.
Br J Cancer. 2013 Aug 6;109(3):610-4. doi: 10.1038/bjc.2013.323.
Epub 2013 Jul 16. PubMed PMID: 23921280; PubMed Central PMCID: PMC3738124.
Association of myeloperoxidase with ovarian cancer
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A,
Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.
Tumour Biol. 2014 Jan;35(1):141-8. doi:10.1007/s13277-013-1017-3.
Epub 2013 Jul 27. PubMed PMID: 23893381; PubMed Central PMCID: PMC4039294.
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation
Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA,
Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.
J Natl Cancer Inst. 2013 Aug7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763. PubMed PMID: 23781004.
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial
Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R,
Taucher S, Wagener A, Marth C, Concin N.
Br J Cancer. 2013 Jul 9;109(1):215-8. doi: 10.1038/bjc.2013.282.
Epub 2013 Jun 13. PubMed PMID: 23764750; PubMed Central PMCID: PMC3708572.
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.
Gynecol Oncol. 2013 Aug;130(2):289-94. doi: 10.1016/j.ygyno.2013.05.013.
Epub 2013 May 18. PubMed PMID: 23694718.
Impact of conization type on the resected cone volume: results of a
retrospective multi-center study
Grimm C, Brammen L, Sliutz G, Weigert M, Sevelda P, Pils S, Reinthaller A,
Polterauer S.
Arch Gynecol Obstet. 2013 Nov;288(5):1081-6.
doi: 10.1007/s00404-013-2873-1. Epub 2013 May 7. PubMed PMID: 23649464.
The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser
P, Reinthaller A, Polterauer S.
BMC Cancer. 2013 Mar 14;13:115. doi: 10.1186/1471-2407-13-115.
PubMed PMID: 23497172; PubMed Central PMCID: PMC3605348.
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer
Aust S, Pils S, Polterauer S, Horvat R, Cacsire Castillo-Tong D, Pils D,
Dudek G, Schmid B, Speiser P, Reinthaller A, Grimm C.
Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):518-24.
doi: 10.1097/PAI.0b013e318284a053. PubMed PMID: 23455184.
HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium
Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S,
Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J.
Onco Targets Ther. 2014 Sep 11;7:1563-9. doi: 10.2147/OTT.S65373. eCollection 2014. PubMed PMID: 25246800; PubMed Central PMCID: PMC4166345.
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F,
Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N,
Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001.
Epub 2014 Jun 2. PubMed PMID: 24889916.
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium
Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S,
Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils
D.Mol Cancer. 2014 Mar 21;13:67. doi: 10.1186/1476-4598-13-67.
PubMed PMID: 24655477; PubMed Central PMCID: PMC3998046.
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma
Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C,
Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H,
Altevogt P.
Oncotarget 2014 Jan 30;5(2):462-72. PubMed PMID: 24497324;
PubMed Central PMCID: PMC3964221.
Association of TAP gene polymorphismsand risk of cervical intraepithelial neoplasia
Natter C, Polterauer S, Rahhal-Schupp J, Cacsire Castillo-Tong D, Pils S,
Speiser P, Zeillinger R, Heinze G, Grimm C.
Dis Markers. 2013;35(2):79-84. doi: 10.1155/2013/368732.
Epub 2013 Jul 28. PubMed PMID: 24288424; PubMed Central PMCID: PMC3774964
Known players, new interplay in atherogenesis: Chronic shear stress and carbamylated-LDL induce and modulateexpression of atherogenic LR11 in human coronary artery endothelium
Bajari TM, Winnicki W, Gensberger ET, Scharrer SI, Regele H, Aumayr K, Kopecky C, Gmeiner BM, Hermann M, Zeillinger R, Sengölge G.
Thromb Haemost. 2014 Feb;111(2):323-32. doi: 10.1160/TH12-12-0924.
Epub 2013 Nov 28. PubMed PMID: 24284991.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E,
Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I,
Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011.
Epub 2013 Oct 28. PubMed PMID: 24176298.
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium
Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli
J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.
BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422.
PubMed PMID: 24044611; PubMed Central PMCID: PMC3848589.
eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women
Groten T, Schleussner E, Lehmann T, Reister F, Holzer B, Danso KA, Zeillinger R.
Arch Gynecol Obstet. 2014 Mar;289(3):581-93. doi: 10.1007/s00404-013-2991-9.
Epub 2013 Sep 8. PubMed PMID: 24013430.
Association of myeloperoxidase with ovarian cancer
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A,
Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF
Tumour Biol. 2014 Jan;35(1):141-8. doi:10.1007/s13277-013-1017-3.
Epub 2013 Jul 27. PubMed PMID: 23893381; PubMed Central PMCID: PMC4039294.
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp
T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet
AG, Vergote I.
Gynecol Oncol. 2013 Oct;131(1):15-20. doi: 10.1016/j.ygyno.2013.07.086.
Epub 2013 Jul 20. PubMed PMID: 23877013.
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van
Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R,
Vergote I, Mahner S, Sehouli J.
J Ovarian Res. 2013 Jun 28;6(1):42. doi: 10.1186/1757-2215-6-42.
PubMed PMID: 23809664; PubMed Central PMCID: PMC3707788.
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium
Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E,
Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser
P, Zeillinger R.
BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.
PubMed PMID: 23551967; PubMed Central PMCID: PMC3639192.
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer
Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M,
Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC.
Int J Gynecol Pathol. 2013 May;32(3):269-76. doi: 10.1097/PGP.0b013e31826a63f8. PubMed PMID:23518910.
The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors
Secky L, Svoboda M, Klameth L, Bajna E, Hamilton G, Zeillinger R, Jäger W,
Thalhammer T.
J Drug Deliv.2013;2013:957605. doi: 10.1155/2013/957605.
Epub 2013 Feb 13. PubMed PMID: 23476785; PubMed Central PMCID: PMC3586502.
Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells
Vaňhara P, Horak P, Pils D, Anees M, Petz M, Gregor W, Zeillinger R, Krainer M.
Int J Oncol. 2013 Apr;42(4):1383-9. doi:10.3892/ijo.2013.1824.
Epub 2013 Feb 12. PubMed PMID: 23404293.
Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S,
Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 2013 Feb;23(2):268-75. doi: 10.1097/IGC.0b013e31827de6b9. PubMed PMID: 23358178.
Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens
Buxhofer-Ausch V, Ausch C, Zeillinger R, Oberkanins C, Dandachi N,
Reiner-Concin A, Kriegshäuser G.
Dis Markers. 2013;34(3):171-7. doi:10.3233/DMA-120960.
PubMed PMID: 23324583; PubMed Central PMCID: PMC3810114.
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study
Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H,
Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J.
Gynecol Oncol. 2013 Feb;128(2):245-51. doi: 10.1016/j.ygyno.2012.11.023.
Epub 2012 Nov 21. PubMed PMID: 23178313
Posttraumatic Stress Disorder After High-Dose-Rate Brachytherapy for Cervical Cancer With 2 Fractions in 1 Application Under Spinal/Epidural Anesthesia: Incidence and Risk Ractors.Kirchheiner K, Czajka-Pepl A, Ponocny-Seliger E, Scharbert G, Wetzel L, Nout RA, Sturdza A, Dimopoulos JC, Dörr W, Pötter R.
Int J Radiat Oncol Biol Phys. 2014 Apr 7.
Manifestation Pattern of Early-Late Vaginal Morbidity After Definitive Radiation (Chemo)Therapy and Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: An Analysis From the EMBRACE Study.
Kirchheiner K, Nout RA, Tanderup K, Lindegaard JC, Westerveld H, Haie-Meder C, Petrič P, Mahantshetty U, Dörr W, Pötter R. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):88-95.
Universal vaccination with the quadrivalent HPV vaccine in Austria: Impact on virus circulation, public health and cost-effectiveness analysis.
Bresse X, Goergen C, Prager B, Joura E.
Expert Rev Pharmacoecon Outcomes Res. 2014 Jan 22.
TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in vivo. Horak P, Tomasich E, Vanhara P, Kratochvílová K, Anees M, Marhold M, Lemberger CE, Gerschpacher M, Horvat R, Sibilia M, Pils D, Krainer M. Sci Rep. 2014 Jan 17;4:3739.
Association of myeloperoxidase with ovarian cancer.Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF. Tumour Biol. 2014 Jan;35(1):141-8.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Eur J Cancer. 2014 Jan;50(1):99-110.
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P. Oncotarget. 2014 Jan 12.
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study.
Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.
J Clin Oncol. 2013 Dec 23.
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
Aust S, Pils S, Polterauer S, Horvat R, Cacsire Castillo-Tong D, Pils D, Dudek G, Schmid B, Speiser P, Reinthaller A, Grimm C.
Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):518-24.
Increase in ezrin expression from benign to malignant breast tumours.
Gschwantler-Kaulich D, Natter C, Steurer S, Walter I, Thomas A, Salama M, Singer CF.
Cell Oncol (Dordr). 2013 Dec;36(6):485-91.
The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer.
Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L, Polterauer S. Eur J Obstet Gynecol Reprod Biol. 2013 Nov;171(1):101-6.
Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM.
Kirisits C, Rivard MJ, Baltas D, Ballester F, De Brabandere M, van der Laarse R, Niatsetski Y, Papagiannis P, Hellebust TP, Perez-Calatayud J, Tanderup K, Venselaar JL, Siebert FA.
Radiother Oncol. 2013 Nov 30.
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva.
de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, Joura EA, Maldonado P, Laco J, Bravo IG, Vidal A, Guimerà N, Cross P, Wain GV, Petry KU, Mariani L, Bergeron C, Mandys V, Sica AR, Félix A, Usubutun A, Seoud M, Hernández-Suárez G, Nowakowski AM, Wilson G, Dalstein V, Hampl M, Kasamatsu ES, Lombardi LE, Tinoco L, Alvarado-Cabrero I, Perrotta M, Bhatla N, Agorastos T, Lynch CF, Goodman MT, Shin HR, Viarheichyk H, Jach R, Cruz MO, Velasco J, Molina C, Bornstein J, Ferrera A, Domingo EJ, Chou CY, Banjo AF, Castellsagué X, Pawlita M, Lloveras B, Quint WG, Muñoz N, Bosch FX; HPV VVAP study group.
Eur J Cancer. 2013 Nov;49(16):3450-61.
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study.
Rössler L, Reich O, Horvat R, de Souza SC, Holl K, Joura EA.
Wien Klin Wochenschr. 2013 Oct;125(19-20):591-9.
High-risk clinical target volume delineation in CT-guided cervical cancer brachytherapy: impact of information from FIGO stage with or without systematic inclusion of 3D documentation of clinical gynecological examination.
Hegazy N, Pötter R, Kirisits C, Berger D, Federico M, Sturdza A, Nesvacil N.
Acta Oncol. 2013 Oct;52(7):1345-52.
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.
Gynecol Oncol. 2013 Oct;131(1):15-20.
Association of TAP Gene Polymorphisms and Risk of Cervical Intraepithelial Neoplasia. Natter C, Polterauer S, Rahhal-Schupp J, Cacsire Castillo-Tong D, Pils S, Speiser P, Zeillinger R, Heinze G, Grimm C.
Dis Markers. 2013;35(2):79-84.
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.
BMC Cancer. 2013 Sep 17;13:422.
» L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.
J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50.
Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer.
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S.
Br J Cancer. 2013 Aug 6;109(3):610-4.
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.
Gynecol Oncol. 2013 Aug;130(2):289-94.
Single line source with and without vaginal loading and the impact on target coverage and organ at risk doses for cervix cancer Stages IB, II, and IIIB: treatment planning simulation in patients treated with MRI-guided adaptive brachytherapy in a multicentre study (EMBRACE).
Nkiwane KS, Pötter R, Tanderup K, Federico M, Lindegaard JC, Kirisits C.
Brachytherapy. 2013 Jul-Aug;12(4):317-23.
Association of myeloperoxidase with ovarian cancer.
Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.
Tumor Biol. 2013 Jul 27.
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial.
Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R, Taucher S, Wagener A, Marth C, Concin N.
Br J Cancer. 2013 Jul 9;109(1):215-8.
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.
Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R, Vergote I, Mahner S, Sehouli J.
J Ovarian Res. 2013 Jun 28;6(1):42.
IL-24 sensitizes tumor cells to TLR3-mediated apoptosis.
Weiss R, Sachet M, Zinngrebe J, Aschacher T, Krainer M, Hegedus B, Walczak H, Bergmann M.
Cell Death Differ. 2013 Jun;20(6):823-33.
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer.
Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M, Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC.
Int J Gynecol Pathol. 2013 May;32(3):269-76.
Impact of conization type on the resected cone volume: results of a retrospective multi-center study.
Grimm C, Brammen L, Sliutz G, Weigert M, Sevelda P, Pils S, Reinthaller A, Polterauer S. Arch Gynecol Obstet. 2013 May 7.
A multicentre comparison of the dosimetric impact of inter- and intra-fractional anatomical variations in fractionated cervix cancer brachytherapy.
Nesvacil N, Tanderup K, Hellebust TP, De Leeuw A, Lang S, Mohamed S, Jamema SV, Anderson C, Pötter R, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):20-5.
Uncertainties in image guided adaptive cervix cancer brachytherapy: impact on planning and prescription.
Tanderup K, Nesvacil N, Pötter R, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):1-5.
Uncertainty analysis for 3D image-based cervix cancer brachytherapy by repetitive MR imaging: assessment of DVH-variations between two HDR fractions within one applicator insertion and their clinical relevance.
Lang S, Nesvacil N, Kirisits C, Georg P, Dimopoulos JC, Federico M, Pötter R.
Radiother Oncol. 2013 Apr;107(1):26-31.
Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytherapy.
Westerveld H, Pötter R, Berger D, Dankulchai P, Dörr W, Sora MC, Pötter-Lang S, Kirisits C.
Radiother Oncol. 2013 Apr;107(1):99-105.
The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.
Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser P, Reinthaller A, Polterauer S.
BMC Cancer. 2013 Mar 14;13:115.
Methylation status of TUSC3 is a prognostic factor in ovarian cancer.
Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M.
Cancer. 2013 Mar 1;119(5):946-54.
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women.
Clark LR, Myers ER, Huh W, Joura EA, Paavonen J, Perez G, James MK, Sings HL, Haupt RM, Saah AJ, Garner EI. Clinical trial experience with prophylactic human papillomavirus 6/11/16/black women.
J Adolesc Health. 2013 Mar;52(3):322-9.
» Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 2013 Feb;23(2):268-75.
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K; HERACLES/SCALE Study Group.
Int J Cancer. 2013 Feb 15;132(4):854-67.
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.
Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R
Gynecol Oncol. 2013 Jan;128(1):15-21.
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: Results from the OVCAD study.
Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J.
Gynecol Oncol. 128:245-251, 2013.
Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.
Buxhofer-Ausch V, Ausch C, Zeillinger R, Oberkanins C, Dandachi N, Reiner-Concin A, Kriegshäuser G.
Dis Markers. 34(3):171-7, 2013.
Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.
Int J Gynecol Cancer. 23(2):268-275, 2013.
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer-a study by the OVCAD consortium.
Melmer A, Fineder L, Lamina C, Kollerits B, Dieplinger B, Braicu I, Sehouli J, Cadron I, Vergote I, Mahner S, Zeimet AG, Castillo-Tong DC, Ebenbichler CF, Zeillinger R, Dieplinger H.
Gynecol Oncol. 128:38-43, 2013.
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.
BMC Cancer. 13:178, 2013.
Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.
Vaňhara P, Horak P, Pils D, Anees M, Petz M, Gregor W, Zeillinger R, Krainer M. Int J Oncol. 42(4):1383-9, 2013.